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CHAPTER 1 
 
BACKGROUND AND INTRODUCTION 
Introduction 
The Acquired Immune Deficiency Syndrome (AIDS) has killed more than 
39 million people since it was identified and clinically defined in 1981 and 1982, 
respectively [1] [2] [3] [4] [5].  The Human Immunodeficiency Virus (HIV) has 
been known as a causative agent for AIDS for over 30 years but it continues to 
have a major impact on global health [6].  Thirty-five million people are currently 
infected with HIV and each year 2.7 million new HIV infections are expected to 
occur [4] [7] [8].     
In order to contribute to the advancement of antiretroviral therapy, this 
dissertation presents research pertaining to both early- and late-stage 
antiretroviral product development by:  (1) highlighting opportunities for 
molecular targeting to impede HIV infection and (2) providing a 
biopharmaceutical rationale to accelerate the development of co-formulated 
antiretroviral drug products.  The first aspect of this body of work presents 
research focused on understanding how the early events of the HIV lifecycle
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influence the infection process.  Single-cycle, fluorescently-tagged HIV and 
virus-like particles were produced and characterized in order to determine factors 
that may account for the observed low infectivity of the virus, quantitate HIV 
infection efficiency, and identify some of the clinically-relevant molecular 
mechanisms that underlie early infection/entry events.  The results from these 
studies will clarify the mechanisms and efficiency of virus binding and infectivity, 
which may influence the development of better strategies for therapeutic 
intervention and/or vaccine development.  
The second aspect of this work presents a provisional assessment of the 
biopharmaceutical characteristics of drug products in the late stages of clinical 
development and/or in the post-market phase for antiretroviral indications in 
order to emphasize how in vitro dissolution strategies can be scientifically valid 
approaches for demonstrating bioequivalence between co-formulated drug 
products and the reference, single-entity products administered in combination.  
Baseline recommendations are presented as a starting place for developing in 
vivo predictive and scientifically valid in vitro dissolution methodology to assess 
fixed dose combinations of various BCS classes.  Thus, by promoting the utility 
of theoretically viable scientific rationale to support simpler and abbreviated 
development pathways, this research highlights potential opportunities to 
increase the availability of co-formulated antiretroviral drug products and 
describes mechanisms by which drug manufacturers and regulators can 
implement science-based approaches to address unmet medical needs and 
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effectively treat some of the world’s deadliest diseases – especially in developing 
countries.  
History and Overview of HIV 
In 1983, Human Immunodeficiency Virus (HIV) was discovered to be the 
etiological agent that causes the Acquired Immune Deficiency Syndrome (AIDS) 
[6].  There are two known types of HIV:  HIV-1 and HIV-2, which are further 
classified into groups of genetically similar isolates (see Figure 1 below). The M-
group of HIV-1, however, comprises the majority of globally prevalent strains of 
HIV [1].  Therefore, the HIV-1 was chosen as the focus of the work described 
herein. 
HIV-1 infects cells involved in the immune system, with CD4+ T 
lymphocytes (i.e., helper T cells) and macrophages acting as the primary 
reservoirs of infection [9].  Following productive infection (i.e., integration of viral 
genome to support viral replication), the host cell is usually destroyed and/or 
impaired so that it can no longer function properly within the immune system.  
As a result of HIV infection, CD4+ T lymphocytes are characteristically depleted 
[10].  Thus, the immune response worsens as the infection spreads, which 
eventually leads to an acquired, immune deficiency (AIDS) as depicted in Figure 
2 .   
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Figure 1  Primate Lentivirus Phylogenetic Relationships [11] 
Highlights genetic relationship between different strains of HIV and the 
Simian Immunodeficiency Virus (SIV). 
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Figure 2  Typical Course of HIV Infection [12]. 
HIV viral load in the blood increases as the number of CD4+ T cells 
dramatically declines. As the immune system deteriorates, it is unable to 
combat other infections.  An HIV-infected individual is diagnosed with 
AIDS when their CD4+ count is ≤ 200 cells/mm3 and they have one or more 
opportunistic infections [13]. 
 
HIV-1 is an enveloped retrovirus that possesses a single-stranded RNA 
genome of approximately 9kb in length (depicted in Figure 3).  Each virion 
carries a non-covalently-associated dimer of genomic RNA.  Coding regions 
comprise the majority of the HIV-1 genome, and these regions are flanked by 
characteristic Long Terminal Repeats (LTRs) at the 5’ and 3’ ends.  The HIV-1 
genome encodes for 15 mature viral proteins, as described in Table 1 and Table 
2.  For HIV to establish an infection, at least one copy of its genomic RNA must 
be reverse transcribed (i.e., produce complimentary DNA from the RNA template) 
into linear proviral cDNA that is subsequently integrated into the host cell’s 
genome.   
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Figure 3  Genomic Arrangement of HIV-1 Landmark Proteins [14] 
 
 
 
  
7 
 
 
Table 1  HIV-1 Structural Proteins [15] 
 
Precursor/ 
Region of 
Genome 
Protein 
Name 
(Abbreviated) 
Nomenclature 
by 
Protein Size 
Known 
Functions 
Primary 
Localization 
Gag 
Matrix 
(MA) p17 
Membrane anchoring; 
Env interaction; 
Nuclear transport of 
viral core 
(myristylated protein) 
Virion 
Capsid 
(CA) p24 
Core capsid Virion 
Nucleocapsid 
(NC) p7 
Nucleocapsid, binds 
RNA Virion 
p6 p6 Binds Vpr Virion 
Pol1 
Protease  
(PR) p15 
Gag-Pol cleavage; 
Maturation Virion 
Reverse 
Transcriptase 
(RT) 
p66 
Reverse transcription; 
RNAse H activity Virion 
Integrase 
(IN) p31 
Integration of proviral 
cDNA into host DNA Virion 
Env 
Envelope 
Surface 
Protein 
(SU) 
gp120 
External glycoprotein 
that binds to CD4 and 
secondary receptors Virion Envelope 
Envelope 
Transmembra
ne Protein 
(TM) 
gp41 
Transmembrane 
glycoprotein that 
mediates membrane 
fusion 
Virion Envelope 
 
  
                                            
 
1 Synthesized as Gag-Pol polyprotein 
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Table 2  HIV-1 Regulatory and Accessory Proteins [15] 
 
Protein 
Name 
(Abbreviated) 
Nomenclature 
by 
Protein Size 
Known 
Functions 
Primary 
Localization
Negative 
Regulatory 
Factor  
(Nef) 
p27 
CD4 and MHC I downregulation 
(myristylated protein) 
Host Cell 
Membrane 
and 
Cytoplasm 
Regulator of 
Virion 
(Rev) 
p19 
RNA transport and stability factor Host Cell 
Nucleus 
Transactivator 
of 
Transcription 
(Tat) 
p16 
Viral transcriptional transactivator 
Host Cell 
Nucleus 
Viral Infectivity 
Factor  
(Vif) 
p23 
Virion maturation; Infectivity Host Cell 
Cytoplasm; 
Virion 
Viral Protein R 
(Vpr) p10 
Nuclear localization of preintegration 
complex; Inhibits cell division Virion Core 
Viral Protein U 
(Vpu) p16 
Release of viral particles; CD4 
degradation 
Host Cell 
Integral 
Membranes 
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HIV-1 infection is believed to be initiated via interactions with cell surface 
receptors such as CD4, which is the primary receptor recognized by the virus.  
The CD4 receptor is commonly expressed on the surface membranes of CD4+ T 
lymphocytes and monocytic cells [16]. Interactions between CD4 and the viral 
envelope glycoprotein, gp120, have been noted as the principal means to 
mediate HIV binding and entry [17].  However, coexpression of chemokine co-
receptors CXCR4 and/or CCR5 is necessary to permit entry into the target cells 
[18] [19] [20] [21]. 
Although the CD4, CXCR4, CCR5 and HIV-1 gp120 interactions are well 
documented, there are still several questions pertaining to HIV entry and 
infectivity.  The literature consistently reports HIV infectivity (a unitless number 
that is calculated by normalizing the virus titer according to the physical number 
of virus particles) to be <0.1% [22] [23] [24].  To-date, however, there is not a 
clear understanding of why HIV possesses such low infectivity.  Some within the 
field have proposed that HIV-1 and other retroviruses, are predominantly 
defective as the extent of rapid mutations (most notably occurring during reverse 
transcription) may lead to the production of noninfectious virus particles [25]. 
Others contest that there are host cell factors that limit HIV-1 infectivity by 
interfering with and/or disrupting the replication cycle [26].  Overall, however, 
there is a great deal of literature suggesting that one of the primary limitations in 
the establishment of a productive HIV infection is the target cell engagement 
and/or entry step.  Specifically, several engineered/artificial methods for 
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increasing interactions between virions and target cells have been documented 
to result in greater infection efficiency.  Such methods include: 
 Spinoculation – method of inoculating cells with virions using 
centrifugation, which results in greater amounts of cell-associated virus 
and a proportional increase in virus replication [27]. 
 Use of polycations – inoculating virions in the presence of positively-
charged molecules (e.g., polybrene, DEAE-dextran) to enhance 
adsorption of virus particles onto target cells and result in greater 
infectivity [24] [28] [29].  
 Overexpression of adhesion molecules – overexpressing adhesion 
molecules on virion-producer cells results in virions that possess more 
adhesion molecules (acquired from budding out of producer cells) and 
enhanced ability to interact with and infect target cells [30] [31] [32]. 
Therefore, it is very plausible that HIV-1 infectivity is primarily limited by the 
ability to efficiently engage target cells.  In fact, there have been some initial 
reports demonstrating that envelope density may affect infectivity for Simian 
Immunodeficiency Virus (SIV) [33] [34].  However, much of the existing HIV-
related literature concerns target cell receptor density rather than the density of 
envelope proteins on the virus [35].   
A study by Platt et al in 2010 also supports the hypothesis that the virus’ 
inability to engage and/or enter target cells may be a main limitation in the 
establishment of a productive infection [36].  They observed virus particles 
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rapidly dissociating from target cells and proposed that the true, inherent level of 
infectivity is masked because of HIV’s inefficient interactions with host cells [36].   
While the results of the study are intriguing, the molecular mechanism behind this 
phenomenon remains unclear. Furthermore, the data are limited by their 
methods for quantitating the virus titer by counting foci of infected cells (which 
may underestimate the number of infections) instead of counting actual number 
of infected cells (which can be achieved using other assays).  Most importantly, 
the quantitative nature of this study is also limited because it only quantitated the 
infectivity of virions that were pre-adsorbed onto target cells (rather than 
quantitating based on the entire virion population).  Therefore, to-date, there has 
been no confirmatory study to quantitatively describe the molecular mechanisms 
for HIV entry and infectivity.   
 
 
Evolution of Therapeutic Approaches to Treat HIV Infection 
Numerous antiretroviral drugs have been approved to treat HIV/AIDS, but 
a complete cure has yet to be discovered.  Highly active antiretroviral therapy 
(HAART), or combinations of antivirals of different drug classes and mechanisms 
of action, has become the standard of care to treat HIV infection. The current U.S. 
Department of Health and Human Services HIV treatment guidelines recommend 
starting treatment with a regimen of three HIV medicines from at least two 
different drug classes among non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors 
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(PIs), fusion inhibitors, entry inhibitors, and integrase strand transfer inhibitors 
(INSTIs).  In general, the treatment guidelines recommend that patients naïve to 
antiretroviral therapy initiate therapy with a regimen that includes two NRTIs in 
combination with an NNRTI, a PI boosted with a pharmacokinetic enhancer, or 
an INSTI [37].  
Approved antiretroviral drugs generally have been limited therapeutically 
because of drug resistance that results from the virus’ ability to rapidly mutate as 
well as the persistence of a reservoir of latently infected cells (i.e., cells that 
possess an inactive, integrated copy of proviral DNA) [38]. In addition to the 
therapeutic limitations of current therapies, these treatment regimens require 
strict compliance.  Unfortunately, many of these drug products have also been 
associated with numerous adverse effects including in some cases, but not 
limited to, diarrhea, nausea and vomiting, lipid abnormalities, and speculated risk 
for myocardial infarction [39] [40] [41] [42]. To-date, there is no prophylactic 
vaccine. 
 The success of current combination therapies for HIV-1 infection is 
largely due their ability to target specific viral targets (e.g., viral protease).  
However, with few exceptions, most of these agents are only effective following 
virus entry and/or infection of a host cell.  The ability to block HIV entry and 
early infection events, on the other hand, would offer enormous advantage as a 
drug development strategy.   
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By blocking target cell entry, the extent of subsequent infections could be 
reduced (in a HIV-infected individual, for example), which may stabilize CD4+ T 
counts over time and delay progression to AIDS since the virus’ ability to enter 
and infect new cells would be diminished. Yet designing effective entry inhibitors 
requires sound evidence regarding the events that facilitate viral entry and lead 
to a productive infection.  The virology field lacks clear insight about these 
events in the viral life cycle and the general understanding of HIV-1 infection 
remains highly disputed. Thus, an understanding of the molecular events of viral 
infectivity will be beneficial to the development of entry inhibitors.  
 With the intention of contributing to the discovery and early-stage 
development of antiretroviral therapy, the first half of this dissertation research 
focused on understanding how the early events of the HIV-1 lifecycle influence 
the infection process.  Central to this research is the underlying hypothesis that 
HIV-1 infectivity is limited by the ability to efficiently engage target cells, which as 
described above, is a theory that is well-supported by various forms of evidence.  
In order to further investigate this theory, the first half of this body of work was 
intended to characterize the virus-cell interactions at the molecular level.   As 
HIV-1 has been reported to only express an average of 14 envelope spike 
proteins per virion – which is an order of magnitude lower than other enveloped 
viruses [43] – one objective for the work presented herein was to investigate the 
envelope-dependent mechanisms that influence the efficiency of HIV-1 
binding/infection.  Thus, HIV-1 was characterized to determine factors that may 
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account for the observed low infectivity of the virus, quantitate HIV infection 
efficiency, and identify some of the clinically-relevant molecular mechanisms that 
underlie early infection/entry events and could potentially become drug targets to 
prevent infection.   
Current Status of Antiretroviral Combination Drug Therapy 
Given the chronic nature of HIV infection and the need for strict patient 
compliance in order to minimize the chances of emerging viral resistance [44], 
fixed dose combinations are commonly utilized for more convenient and 
simplified dosing regimens, which may result in greater levels of patient 
compliance. Several studies have demonstrated that, when compared to 
regimens requiring multiple tablets, single-tablet HIV regimens are associated 
with greater adherence; and as a result, lead to more viral suppression [45] [46] 
[47].  However, not all available, single-entity antiretroviral drugs have been 
incorporated into approved, co-formulated antiretroviral combination drug 
products and, although it could significantly aid the development of combination 
drug products globally, scientifically justified criteria for demonstrating 
bioequivalence to support the efficacy of fixed dose combination regimens 
relative to their individual drug components have yet to be established [38] [48].  
 In order to contribute practical scientific data to advance antiretroviral 
therapy in the later stages of development, the second half of this dissertation 
research focused on providing a biopharmaceutical rationale to accelerate the 
development of co-formulated antiretroviral drug products.  Central to this 
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research is the underlying theory that, a well-designed, oral fixed-dose 
combination drug product, formulated with individual drugs that exhibit linear and 
non-interacting absorption, distribution, metabolism and excretion/elimination 
(ADME), in the absence of excipients that significantly affect bioavailability, 
should have the same in vivo dissolution characteristics and hence absorption 
profiles as the constituent, single-entity drug products in the same dosage form, 
and, as a result,  will be bioequivalent, regardless of the biopharmaceutical 
classification of the active ingredients.   34 single-entity drug products and 22 
fixed dose, co-formulated, combination drug products with HIV indications in late 
stage clinical development (Phase 2 or beyond) or post-marketing phase were 
assessed in order to promote the utility of this theoretically-viable scientific 
rationale.  Thus, the second half of this body of work highlights potential 
opportunities to increase the availability of co-formulated antiretroviral drug 
products – especially in developing countries – in order to meet the significant 
global unmet medical need for HIV/AIDS therapy. 
Thesis Overview 
This work is comprised of an investigation of the molecular mechanisms 
that form the basis of HIV-1 infectivity and an evaluation of both investigational 
and approved antiretroviral [combination] drug regimens.   The results from the 
first portion of this thesis further the current understanding of the molecular 
mechanisms underlying HIV entry and infectivity, which may influence the 
development of better strategies for therapeutic intervention. In the second half of 
16 
 
 
the project, antiviral drug products that are approved or in the late-stage pipeline 
were provisionally classified and evaluated in relation to product substitutability 
and/or interchangeability standards for both single-entity and combination drug 
products.  The results from both aspects of this research provide a current and 
forward-looking view of antiretroviral therapy that will aid the development of 
therapeutic approaches to combat one of the world’s most serious viral infections.  
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CHAPTER 2 
 
OPTIMIZED INFECTIVITY OF EGFP-TAGGED, SINGLE-CYCLE HIV-1 
 
Abstract 
The infectivity of cell-free HIV-1 is consistently reported to be less than 
0.1% and the mechanisms influencing this low infectivity are not yet fully 
understood. Some hypothesize that this observed low infectivity results from the 
presence of defective HIV-1 particles, formed from mutations introduced in the 
reverse transcription step of virus replication. Using molecularly cloned HIV-1 
that is capable of only a single round of infection, we can bypass the reverse 
transcription step during virus production in order to investigate this hypothesis 
and the extent to which infectivity can be influenced by other factors during virus 
production.  Herein we show that optimal infectivity is obtained by harvesting 
virions from culture media 18 hours after transfection, with complete media 
changes 4-6 hours post-transfection.  This optimal infectivity appears to 
primarily result from the emergence of “noninfectious” virus particles at later time 
points.  Our data demonstrate that HIV-1 infectivity increases in the presence of
18 
 
 
greater amounts of viral envelope glycoproteins.  Thus, the larger proportion of 
“noninfectious” virus particles apparent in harvested virus cultures at later time 
points may be attributable to the production of virus lacking sufficient amounts of 
envelope glycoproteins.  However, although we demonstrate ways by which 
virus infectivity can be optimized by varying parameters to enhance culture and 
production conditions, the overall infectivity of HIV-1 remains low.  This 
suggests that the observed low infectivity of the virus is principally attributable to 
other, potentially-related, mechanism(s).   
Introduction 
Infectivity, a unitless number that quantitates the proportion of virus 
particles that are infectious, is a critical parameter for characterizing the human 
immunodeficiency virus type 1 (HIV-1).  The infectivity of HIV-1 is consistently 
reported to be less than 0.1% [22] [23] [24].  There is not yet a clear, 
confirmatory understanding of why HIV-1 possesses such low infectivity, but 
there is a great deal of literature suggesting that one of the primary limitations in 
the establishment of a productive HIV infection is the target cell engagement 
and/or entry step.  In fact, several engineered/artificial methods for increasing 
interactions between virions and target cells have been documented to result in 
greater infection efficiency.  Spinoculation, a method of inoculating cells with 
virions using centrifugation, for example, results in greater amounts of cell-
associated virus and a proportional increase in virus replication [27].  
Furthermore, inoculating virions in the presence of positively-charged molecules 
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(e.g., polybrene) has been shown to enhance adsorption of virus particles onto 
target cells and result in greater infectivity [24] [28] [29]. And the overexpression 
adhesion molecules on virion-producer cells has also been shown to result in 
virions that possess more adhesion molecules (acquired from budding out of 
producer cells) and enhanced ability to interact with and infect target cells [30] 
[31] [32].  Therefore, it is plausible that HIV-1 infectivity is primarily limited by the 
ability to efficiently engage target cells.   
On the other hand, however, some have hypothesized that this observed 
low infectivity results from the presence of defective HIV-1 particles, formed from 
mutations introduced in the reverse transcription step of virus replication [25].  
This theory is supported by the well-documented, naturally high error rate of HIV 
reverse transcriptase [49] [50] [51]. Furthermore, the identification of defense 
mechanisms, such as APOBEC3 cytidine deaminases, in the host cell that can 
influence the rate of mutation during the reverse transcription step of virus 
replication also strongly point to the possibility that the low infectivity of HIV-1 
might be due to the presence of large numbers of defective virions resulting from 
mutations introduced to the proviral DNA during reverse transcription [52] [53].   
Using molecularly cloned HIV-1 that is capable of only a single round of 
infection, we can bypass the reverse transcription step during virus production 
and essentially eliminate the influence of reverse transcriptase errors and 
APOBEC3 in order to investigate this hypothesis and determine the extent to 
which infectivity can be influenced by other factors during virus production.   
20 
 
 
Herein we specifically demonstrate that the culture conditions commonly used to 
produce cell-free HIV-1 in cultured media significantly influence the resulting 
infectivity of virions and can result in the production of a greater proportion of 
defective virus over time.  These results emphasize the optimal conditions for 
producing cell-free virus and point to a potential molecular mechanism, related to 
the alternate theory of inefficient virus-cell interactions, which may more 
significantly impede the infectivity of HIV-1 in plasma or cultured media.  
Materials and Methods 
Production of single-cycle HIV-1 virions. 
Virions were produced by transfecting HEK 293T/17 cells (ATCC, 
Manassas, VA) as previously described [54]. Briefly, 293T were cultured at 37oC 
with 5% CO2 in DMEM supplemented with 10% FBS (HyClone Laboratories, 
Logan, UT) and seeded overnight in culture media.  Using the TransIT LT-1 
transfection reagent (MirusBio, Madison, WI), HIV virions carrying free EGFP 
were generated by transfection with variable amounts of pNL4-3E- plasmid, 
pNL4-3E-MA-EGFP-CA plasmid and pcDNA3.1REC.   In certain experiments, 
after a specified number of hours of incubation at 37oC, the culture media (with 
transfection reagents) was removed and replaced with fresh culture media.  The 
37oC incubation continued for an additional period.  At the experimentally-
determined time point post transfection, the culture media, containing EGFP-
labeled single-cycle virions was collected and filtered through a 0.45-mm syringe 
filter (Millex-HV PVDF, Millipore).  The filtrate was then aliquoted on ice, flash-
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frozen in a dry ice/ ethanol bath and stored in a -80oC freezer.  Subsequent 
analysis using p24 ELISA (HIV-1 p24 Antigen Capture Kit, Advanced Bioscience 
Laboratories, Rockville, MD) was conducted to determine the number of virus 
particles in a specified volume, assuming 2,500 molecules of p24 per virion. 
Calculating the Infectivity of free-EGFP HIV-1. 
Infection assay in TZM-bl cell line.  The infectivity of virions was 
calculated by normalizing the virus titer (i.e., number of infectious units in a 
certain volume) to the physical number of virus particles present in the specified 
volume.  The titer was be determined by using an established β-galactosidase-
based infection assay.  This assay relies upon the TZM-bl indicator cell line - a 
genetically engineered HeLa-derived cell line that expresses CD4, CXCR4, and 
CCR5 [55] [56].  TZM-bl cells function as indicators of HIV infection because 
they also possess Luciferase and bacterial β-galactosidase reporter genes, 
which are driven by an HIV LTR promoter.  This LTR promoter is induced to 
express the reporter enzymes following HIV infection when the viral protein Tat 
(Transactivator of transcription) is produced [57].  Thus, in theory, only infected 
cells will express the reporter genes. These infected cells can be detected by 
providing a chromogenic substrate for either of the reporter enzymes.  For these 
studies, infected cells will be quantitated by using 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (X-gal) as a substrate for β-galactosidase.  β-
galactosidase catalyzes the hydrolysis of X-gal and produces a blue-colored 
byproduct, 5,5'-dibromo-4,4'-dichloro-indigo. 
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The infectious titer of HIV-1 virions can therefore be determined by 
enumerating the number of blue TZM-bl cells following inoculation with various 
dilutions of the virus stock in accordance with the following equation: 
mL
 UnitsInfectious
(mL) Volume Inoculum
mL 1
FactorDilution 
Cells TZMbl Blue#Titer 
 
 
TZM-bl cells (cat#8129, NIH AIDS Research and Reference Reagent 
Program) were cultured at 37oC with 5% CO2 in DMEM supplemented with 10% 
FBS (HyClone Laboratories, Logan, UT).  Prior to tenth passage, TZM-bl cells 
were trypsinized, counted, sedimented by centrifugation at 1,000g for 5 minutes 
and resuspended in DMEM with 10% FBS.  8X104 TZM-bl cells in a 1-ml culture 
volume were seeded in each well of a 12-well plate one day prior to infection. 
EGFP-labeled HIV-1 particles (obtained from stocks stored at -80oC) were added 
to these pre-seeded aliquots of TZM-bl cells in 100 µl of DMEM with 10% FBS 
and DEAE dextran (final concentration 20 mg/ml).  The virion and TZM-bl cell 
mixture was incubated at 37oC for 2hrs with gentle rocking every 30 min. At the 
end of two hours, 1 ml of complete media was added to each well and the 
incubation was continued at 37oC for 48 hours with 5% CO2.  After 2 days of 
incubation, cells were fixed in 2% gluteraldehyde at room temperature for five 
minutes. Cells were then washed three times with PBS, and stained for 50 min at 
37oC using cell staining solution provided in the beta-galactosidase staining kit 
(Mirus Bio, Madison, WI). Cells were washed three times with milliQ water and 
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the number of blue cells in each well was counted using a 10X objective on a 
Nikon TS100-F inverted microscope. 
p24 ELISA.  Calculating infectivity also depends on quantitating the 
number of physical virion particles in a given volume.  Expression of HIV-1 p24 
structural protein has been demonstrated to correlate with viral loads in vitro [58]. 
Thus, in these studies, a commercially available p24 Enzyme-Linked 
Immunosorbent Assay (ELISA) was utilized to quantitate the number of virions.  
The ELISA enables detection and quantification of p24 in a given volume through 
absorbance readings that can be extrapolated to a p24 concentration according 
to a standard curve of reference samples with known p24 concentrations.  
Specifically, based on the estimation of there being approximately 2.5 million 
virus particles per ng of p24 [59] [60], the number of HIV-1 particles in a specified 
volume was calculated as follows: 
 
mL
p24 of pg
FactorDilution  Curve Standard of Slope
 Value Absorbance Sample
   

mL
particles HIV of#
mL
p24 of pg
p24 of ng
particles HIV 105.2
pg 1000
ng 1 6  
Infectivity Calculation.  Using the titer and p24 values, the infectivity, 
i.e., the fraction of single-cycle free-EGFP HIV-1 that is infectious, was 
quantitated as follows:  
100
mLParticles HIV of# Total
mL UnitsInfectious nfectivityI    
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Results and Discussion 
In order to quantitate the efficiency of HIV infection, single-cycle HIV-1 
pseudovirions carrying free molecules of Enhanced Green Fluorescent Protein 
(i.e., free-EGFP) were utilized.  To produce free-EGFP virions, the proviral HIV-
1 DNA was engineered to carry an EGFP coding sequence flanked by two HIV 
protease cleavage sites within the gag domain of viral genome (see Figure 4). 
Upon virion maturation, the Gag polyprotein is proteolytically cleaved such that 
free molecules of EGFP exist inside of the virions, as depicted in Figure 5. 
 
Figure 4  Depiction of EGFP Insertion in HIV-1 Genome [61] 
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Figure 5  Viral Matruation and Production of “Free” EGFP within Virions 
[62] 
 
The backbone of the single-cycle, free-EGFP virions was derived from an 
envelope-deficient (E-) HIV-1 plasmid. Therefore, progeny virus were not capable 
of producing the HIV-1 envelope proteins that are necessary for subsequent 
rounds of infection. Instead, a single round of infection is achieved by expressing 
the envelope deficient proviral DNA in the presence of a separate envelope 
expression plasmid [63], as described in Materials and Methods.   
The usual transfection procedures call for an equal weight mixture of 
provirus and envelope plasmids and specify that virions should be harvested 48 
hours post-transfection [64].  However, there is no well-documented rationale for 
harvesting virus at 48 hours.  To investigate this whether timing impacts 
infectivity during the production of cell-free single-cycle HIV-1, a range of 
common harvesting time points were studied.  Consistent with previous reports 
[36], EGFP-labeled, single-cycle HIV-1 harvested from culture media after 18 
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hours has higher infectivity (Figure 6A) and Figure 6B).  Per the modest 
changes in the infectious titer and corresponding  significant increase in virus 
concentration, as shown in Figure 6C and Figure 6D, respectively,  this optimal 
infectivity appears to primarily result from the emergence of “noninfectious” virus 
particles at later time points.   
Consistent with the significant increase in p24 concentration (Figure 6D), 
this observed harvest time-dependency could be a result of the greater 
production of defective virions at later time points.  However, it also possible that 
there is actual loss of virus infectivity over time.  We elected to investigate our 
findings in greater detail to determine whether there are specific mechanisms to 
explain the correlation between higher infectivity and early harvesting time. For 
example, if the correlation is due to the actual loss of infectivity over time, it is 
plausible that certain “environmental factors” in the cell culture may be promoting 
a loss of infectivity. Virus harvested at later times would be subject to the cell 
culture conditions for longer periods and thus, the impact on infectivity would be 
more apparent and consistent with our observations.  Therefore, in order to 
distinguish between an actual loss of infectivity and the production of defective 
virions, we examined the impact of various environmental factors to determine if 
the cell culture/virus production conditions might be promoting a loss of infectivity. 
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Panel (A) - Data presented are representative of the mean of 2 replicates 
under each experimental condition, which suggest a general trend for 
increased infectivity at shorter harvest times.  Panels (B), (C), and (D) - 
Data presented are representative of the mean ± SD (for Panel (B), the SD 
was calculated per propagation of error in the experimental values) of 3 
individual replicates (n=3), each of which was studied in duplicate for each 
experimental condition.  Statistical significance between the experimental 
conditions was tested using an unpaired t test.  The t-statistic was 
compared to the corresponding critical values for a two-tailed test and df = 
4 in standard statistical tables.  Asterisks denote statistical differences at 
a 0.05 significance level. 
 
 
Per the experimental method, single-cycle HIV-1 is collected and 
harvested from the cell culture media. Prior to harvesting, however, virions reside 
in culture with the 293T producer cells and are subject to the cell culture 
conditions. Although media change is not required following transfection with the 
Figure 6  HIV-1 Infectivity is Dependent on Harvest Time 
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TransIT LT-1 reagents (Mirus Bio, Madison, WI), the cell culture conditions may 
still be less than ideal.  Therefore, we studied the impact of refreshing the 
complete media at various time points following transfection.  As shown in 
Figure 7, infectivity increases substantially when media changes are introduced – 
and optimal infectivity is obtained with media changes at 4-6 hours post-
transfection.    
Figure 7  Media Changes Increase Infectivity 
 
Data presented are representative of the mean ± SD (the SD was calculated 
per propagation of error in the experimental values) of 3 individual 
replicates (n=3), each of which was studied in duplicate for each 
experimental condition.  Statistical significance between the experimental 
conditions was tested using an unpaired t test.  The t-statistic was 
compared to the corresponding critical values for a two-tailed test and df = 
4 in standard statistical tables. Asterisks denote statistical differences (vs. 
no media change, time = 0) at a 0.05 significance level. 
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Since changing the media post-transfection resulted in higher infectivity 
and pH is an important parameter for maintaining viable cell culture, we 
monitored the pH over time to assess whether pH changes could be promoting a 
loss of virus infectivity over time.  As shown in Table 3, however, the pH 
remained relatively constant through the time of harvest.  Therefore, pH 
changes do not explain the observed decline in HIV-1 infectivity. 
 
Table 3  pH Changes Do Not Promote Loss of Infectivity 
 
 
Transfection reagents are well-known for cytotoxicity [65] and it is 
possible that HIV-1might also be sensitive to transfection reagents.  To assess 
whether prolonged exposure to transfection reagents remaining in the cell culture 
might promote loss of virus infectivity, we conducted a stability assay with 
harvested virus.  The relative infectivity, calculated as the ratio between the 
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infectivity of virus incubated in complete media only and the infectivity of virus 
subject to transfection reagent (diluted in complete media to mimic conditions of 
virus production) demonstrates that the infectivity was consistently comparable 
over time.  Therefore, the presence of transfection reagents does not explain 
the observed decline in HIV-1 infectivity.   
 
Figure 8  Presence of Transfection Reagents Does Not Promote Loss of 
Infectivity 
 
Ratios were calculated using the means ± SD of 3 individual replicates 
(n=3), each of which was studied in duplicate for each experimental 
condition.  Statistical significance between the experimental conditions 
was tested using an unpaired t test.  The t-statistic was compared to the 
corresponding critical values for a two-tailed test and df = 4 in standard 
statistical tables at a 0.05 significance level. No statistical differences were 
observed (vs. control at 0 hours). 
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To further investigate and distinguish between low infectivity resulting 
from the production of greater proportions of defective virions at later time points 
and the loss of virus infectivity over time, we considered that the biophysical 
instability of virion particles is a known contributor to the infectivity decay of HIV-1 
[22].   However, such reports do not yet fully explain why HIV-1 infectivity is 
consistently observed to be so low.  Notably, even under optimal culture 
conditions, we continued to observe infectivity on the same low order of 
magnitude.  We, therefore, wanted to determine whether the overall low 
infectivity of HIV-1 could be attributed to the presence of defective virions 
resulting from mechanisms other than revere transcription-associated mutations 
(which our experimental system bypassed) during virus production.  Evidence 
supporting the presence of defective virions would be consistent with our 
observations of increased virus production without a corresponding increase in 
infectivity as well as the marked impact of changing the media post-transfection 
which, theoretically, could reduce the concentration of defective virions.  
Along these lines, there are reports of how stoichiometries of viral 
proteins influence stability of HIV-1 and the incorporation of viral envelope 
glycoproteins has specifically been implicated in HIV-1 infectivity decay [66].  
There are, in fact, still many questions about the distribution of viral proteins 
during virus assembly and it is possible that defective, less infectious, and/or 
unstable virions could result from progeny virus incorporating unfavorable 
amounts of viral proteins.   Therefore, we sought to demonstrate and assess 
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the extent to which varying the stoichiometry of viral proteins might influence the 
infectivity - as this might provide a molecular explanation for the observed low 
infectivity of HIV-1.  
Our method of producing single-cycle virus was conducive to 
investigating how the incorporation of variable amounts of viral proteins might 
influence the infectivity of HIV-1.  Specifically, since viral envelope protein 
incorporation results from expression of HIV-1 DNA encoded on a plasmid that is 
separate from the remainder of the viral genome, we could vary the envelope 
stoichiometry by changing the amount of envelope-encoding DNA used to 
produce our single-cycle virus.   
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Panel (A) - Western blot for HIV-1 envelope glycoprotein 120 (gp120) 
confirming successful production of virus with variable amounts of 
envelope spike proteins.  Panel (B) - The corresponding infectivity 
calculations, representative of the mean ± SD of 3 replicates, which 
suggest a general trend for increased infectivity with greater amounts of 
envelope incorporation.  
 
As shown above (Figure 9A), we successfully produced virus with 
variable amounts of envelope spike proteins.  Our data demonstrate that HIV-1 
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Figure 9  Greater Amounts of Envelope Glycoproteins Increase Infectivity
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infectivity increases with greater amounts of envelope glycoprotein (Figure 9B);  
thus indicating that the larger proportion of “noninfectious” virus particles 
apparent in harvested virus cultures at later time points following transfection 
may be due to the production of defective virus, lacking sufficient amounts of 
envelope glycoproteins.  Yet, because the overall infectivity still remained 
relatively low under these optimized conditions, this mechanism does not to fully 
explain the reasons underlying the consistent reports of low HIV-1 infectivity. 
Conclusion 
 We have studied the infectivity of single-cycle HIV-1 and determined that 
harvesting time, media changes, and the expression of envelope proteins all 
impact virus infectivity and indicate that a greater proportion of defective virus is 
produced at later time points.  Our data are consistent with prior reports 
regarding the role of biophysical instability and/or lack of envelope glycoproteins 
in diminishing virus infectivity.  However, although we demonstrate ways by 
which virus infectivity can be optimized by varying these conditions, the overall 
infectivity of HIV-1 remains low – suggesting that the observed low infectivity of 
the virus is principally attributable to other, potentially-related, mechanism(s).  
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CHAPTER 3 
 
QUANTITATION OF HIV-1 INFECTION EFFICIENCY 
Abstract 
There is not a clear understanding of why the infectivity of cell-free HIV-1 
has been consistently reported to be several orders of magnitude lower than 
other enveloped viruses (i.e., HIV-1 infectivity is typically observed as less than 
0.1%).  In order to gain more knowledge about the factors influencing HIV-1 
infectivity, we sought to quantitate the overall efficiency of infection.  Specifically, 
by combining the well-established TZM-bl indicator assay with fluorescent 
techniques, we were able to quantitate the overall infection efficiency of HIV-1 as 
a function of virus concentration.     
Introduction 
Due to the apparently low infectivity in plasma or culture media, 
retroviruses such as HIV-1 have generally been perceived as being 
predominantly defective.  In the case of HIV-1, for example, typically less than 
0.1% of the total cell-free virus concentration will produce infections [22] [23] [24].
36 
 
 
It was originally believed that this observed low infectivity results from the 
presence of defective HIV-1 particles, formed from mutations occurring during 
reverse transcription [25].   Yet, despite the fact that defective virus particles 
have been well-characterized for other RNA viruses, there is not conclusive 
evidence to directly associate the low infectivity of HIV-1 with the existence of 
large quantities of defective particles.  On the contrary, there are several pieces 
of evidence to support the notion that the inefficiency of HIV-1 interactions with 
target host cells is a primary factor impacting this overall low infectivity.  The use 
of polycations like DEAE dextran [24] [28] [29], for example, as well as the 
increasingly popular practice of applying centrifugal force [27] (“spinoculation”) to 
promote virus-cell interactions, have been demonstrated to substantially increase 
the infectious virus titer.  Furthermore, our recent studies limiting the presence 
of defective particles (by bypassing the reverse transcription step during virus 
production) also suggest that the overall observed infectivity of HIV-1 is largely 
influenced by host cell interactions [54].  Consistent with this finding, it has been 
demonstrated that, after VSV-G pseudo-typed HIV-1 enters a host cell and 
initiates reverse transcription, it is capable of establishing infection with 
approximately 13% efficiency [67].  As this infection efficiency is at least two 
orders of magnitude greater than the purported infectivity of the virus, it supports 
the notion of the primary hindrance(s) to the overall efficiency of HIV-1 infection 
occurring prior to the initiation of reverse transcription.   
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With this in mind, we sought to quantitate the overall infection efficiency 
of HIV-1 by determining the proportion of cells that become infected after 
inoculation with various concentrations of virus.  By comparing the proportion of 
cells that become infected to the fraction of cells that originally had virions 
bound/internalized (as determined by flow cytometry), we also calculated the 
efficiency of HIV-1 infection following attachment to cells.   
Materials and Methods 
Production of single-cycle HIV-1 virions. 
Virions were produced by transfecting HEK 293T/17 cells (ATCC, 
Manassas, VA) as previously described [54]. Briefly, 293T were cultured at 37oC 
with 5% CO2 in DMEM supplemented with 10% FBS (HyClone Laboratories, 
Logan, UT) and transfected at the fifth passage. 106 293T cells were seeded 
overnight in a T-75 flask with 10ml of culture media.  Using the TransIT LT-1 
transfection reagent (MirusBio, Madison, WI), HIV virions carrying free EGFP 
were generated by transfection with 4.0µg pNL4-3E- plasmid, 4.0µg pNL4-3E-
MA-EGFP-CA plasmid and 0.8µg pcDNA3.1REC.   After 6 hours of incubation 
at 37oC, the culture media (with transfection reagents) was removed and 
replaced with 16ml of fresh culture media.  The 37oC incubation continued for 
an additional 12 hour period.  At 18 hours post transfection, the culture media, 
containing EGFP-labeled single-cycle virions was collected and filtered through a 
0.45-mm syringe filter (Millex-HV PVDF, Millipore).  The filtrate was then 
aliquoted on ice, flash-frozen in a dry ice/ ethanol bath and stored in a -80oC 
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freezer.  Subsequent analysis using p24 ELISA (HIV-1 p24 Antigen Capture Kit, 
Advanced Bioscience Laboratories, Rockville, MD) was conducted to determine 
the number of virus particles in a specified volume, assuming 2,500 molecules of 
p24 per virion. 
Infection assay in TZM-bl cell line. 
TZM-bl cells (cat#8129, NIH AIDS Research and Reference Reagent 
Program) were cultured at 37oC with 5% CO2 in DMEM supplemented with 10% 
FBS (HyClone Laboratories, Logan, UT).  Prior to tenth passage, TZM-bl cells 
were trypsinized, counted, sedimented by centrifugation at 1,000g for 5 minutes 
and resuspended in DEAE dextran (final concentration 20 mg/ml) and/or DMEM 
with 10% FBS.  EGFP-labeled HIV-1 particles were added to aliquots of TZM-bl 
cells in 1.5ul Eppendorf tubes up to a total volume representative of each MOP 
condition.  The virion and TZM-bl cell mixture was incubated in suspension on a 
fixed-speed nutator (Fisher Scientific) at 37oC for 2hrs.  Following the 2hr 
inoculation, samples were immediately placed on ice to halt the infection process.  
Samples were kept on ice/at 4oC and washed (i.e., centrifugation at 1,000g for 5 
minutes followed by resuspension) with DMEM containing 10% FBS three times 
to remove any unbound virions.  However, the supernatant from the first wash 
was collected and flash frozen for later analysis via p24 Antigen Capture Kit 
(Advanced Bioscience Laboratories, Rockville, MD) in accordance with the 
manufacturer’s instructions.  Following the washing step, 2 aliquots (containing 
approximately 8x104 cells) from the cell-virion samples were seeded in 1ml of  
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DMEM with 10% FBS in 24-well plates.  The samples were further incubated at 
37oC with 5% CO2 for 2 days.  After 2 days of incubation, cells were fixed in 2% 
gluteraldehyde at room temperature for five minutes. Cells were then washed 
three times with PBS, and stained for 50 min at 37oC using cell staining solution 
provided in the beta-galactosidase staining kit (Mirus Bio, Madison, WI).    Cells 
were washed three times with milliQ water and the number of blue cells in each 
well was counted using a 10X objective on a Nikon TS100-F inverted microscope. 
Flow cytometry analyses 
Following inoculation in suspension and after aliquots were taken for 
beta-galactosidase staining, the remaining TZM-bl cells were resuspended in 4% 
paraformaldehyde for 10 minutes at room temperature.  After fixation, the 
samples were washed (i.e., centrifugation at 1,000g for 5 minutes followed by 
resuspension) in PBS two times.  The samples were kept at 4oC until 
subsequent flow cytometry analysis (using BD FACSCanto II flow cytometer).  
The resulting measurements of fluorescence intensity were analyzed via original 
Matlab code, designed to fit data to the sum of two log-normal distributions. 
Results 
Herein we have utilized flow cytometry to quantitate the infection 
efficiency of HIV-1.  Our data show that the inherent efficiency of HIV-1 infection 
is dependent upon the multiplicity of virus particles (MOP).  Interestingly, at high 
MOP values, we observed a significant limitation in the infection efficiency.   
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MOP Dependence of HIV Infection 
In order to quantitate the efficiency of HIV-1 infection, it was necessary to 
study both the extent of virion binding/internalization and the number of cells 
infected. For direct comparisons of both quantitative measures in these 
experiments, we utilized TZM-bl cells, which carry a β-galactosidase reporter that 
is expressed upon productive HIV infection [57].  Because infected cells can be 
stained blue following the β-galactosidase-mediated reaction with X-gal, the 
chromogenic substrate, this reporter allowed us to visibly determine the number 
of infected cells under different inoculation conditions. 
Specifically, we quantitated the fraction of blue, infected cells as a 
function of the multiplicity of particles (MOP).  The MOP refers to the ratio 
between the physical number of HIV-1 particles (as determined by p24 ELISA) 
and the number of potential CD4+ target cells.  In our experiments, the MOP 
value is based on the total number of virus particles introduced to a defined cell 
population at the start of the inoculation. Clinically, it is well known that viral loads 
and CD4+ cell counts fluctuate over the duration of infection and in accordance 
with disease progression in HIV-infected individuals.  In fact, over a typical 
course of infection, the MOPs cover a wide range, potentially rising as high as 
1000 virus particles/CD4+ T cell or more (following the onset of AIDS) [12].   
Our experimental conditions were designed to allow us to study HIV-1 infection 
efficiency over a range of clinically-relevant MOP values.  Furthermore, because 
we utilized single-cycle virions (as described in Methods), we are able to obtain 
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an accurate measure of the overall infection efficiency of a single round of virus 
replication.  As the fraction of infected cells is determined in accordance with the 
total number of virus particles in the inoculum our measure of the overall infection 
efficiency will also take into account any possible influences resulting from 
inefficient/unproductive virus binding.     
As presented in Figure 10, we observed that the percentage of cells that 
became infected increases with higher MOP.  And, per the continual increase 
seen through the regime of extremely high MOPs (i.e., 2900 and 5008), we 
projected that the infection efficiency would eventually reach a point of saturation 
– where basically every cell would become infected.  However, because the 
infectivity of this single-cycle virus was estimated to be 0.02% - 0.03% 
(determined according to previously described protocol, see Methods), we 
expected to have an average 1 or more “infectious” virus particles per cell at 
MOP values greater than or equal to 5000.   Hence, we were surprised to find 
that the efficiency of infection did not approach saturation within the range of 
MOPs tested.  Although there was concordance with projected values in the low 
MOP regime, the actual fraction of cells that became infected was lower than 
anticipated at high MOP values (Figure 10B and C).  In fact, as listed in Table 4, 
there is a large discrepancy in the projected proportion of infected cells, based on 
the infectivity calculated at low virus concentrations (MOP=12), and the 
experimentally-determined fraction of cells that became infected.  It is unlikely 
that this unexpectedly low proportion of infected cells is attributable to limitations 
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in the experimental method and/or substrate availability because we observe a 
continual increase in the fraction of cells infected as a function of MOP overall, 
which we confirmed by additional, repetitive experiments.   Instead, this 
discrepancy suggested that there were other factors influencing virion infectivity, 
which may become more prominent in the higher range of MOP values.  
Therefore, we determined the overall infection efficiency of each regime 
separately.  A linear fit of the data (Figure 10B) revealed that the overall 
efficiency of HIV-1 infection is approximately 0.023% for MOP≤1000.  The 
corresponding infection efficiency under high MOP conditions (i.e., MOP≥1000) is 
estimated to be 0.009% (Figure 10C).  Our data demonstrate that infection was 
more efficient at low MOP.  Additional studies were warranted to characterize 
this MOP dependence. 
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Figure 10  Fraction of Cells Infected and Overall Infection Efficiency  
 
Panel (A) - Data demonstrates that increasing fractions of infected cells (as 
determined by the TZM-bl indicator assay) are observed at higher MOP.  
Values represent the mean of 2 replicate samples ± SD.   The overall 
infection efficiency was determined according to a linear fit of the fraction 
of infected cells as a function of MOP for MOP≤1000 (Panel (B)) and 
MOP≥1000 (Panel(C)). Experimental values from Panel (A) are plotted as 
filled circles, the blue line represents the expected values (per Table 4) and 
the red line corresponds to the linear fit.  The relative infectivity can be 
determined from the slope of each linear fit, as shown.  The data support a 
general trend of greater infectivity for MOP≤1000.  
B C
A 
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Table 4  Overall Infection Efficiency:  Observed Fraction of Infected Cells 
vs. Expected Fraction of Infected Cells  
 
Comparison of the projected fraction of cells to become infected (Expected 
column) and the experimentally measured fraction of cells to become 
infected (Observed Column) reveals that values are consistent at 
MOP≤1000. However, there are large discrepancies at high MOP values.  
Expected values were projected according to the calculated infectivity 
(infectious titer normalized to p24) at an MOP of 12.  Observed values 
represent the mean ± SE of 2 repeat samples. 
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Limited Efficiency of HIV Infection 
While rapid dissociation has been previously suspected to play a role in 
masking the inherent infectivity of HIV-1 [36], the impact of these quick 
interactions is not expected to change with increasing MOPs.   Therefore, we 
began to investigate the role of host cell binding interactions underlying our 
determination of the infection efficiency for HIV-1.  Specifically we sought to 
determine the infection efficiency as: the relative ratio between the proportion of 
cells with virions associate (i.e., bound/internalized) immediately following 
inoculation and the proportion of cells that become infected.  This calculation 
represents an alternate method for estimating the infection efficiency as a 
function of the extent of virion association with host cells.  By comparing the 
infection efficiency following virion association, to the overall infection efficiency, 
we can elucidate the significance of limitations posed by the engaging a host cell.   
To conduct this analysis, we utilized single-cycle HIV-1 virions 
engineered (as described in Methods) to carry free molecules of enhanced green 
fluorescent proteins (EGFPs).  As cells with virions bound/internalized 
presented fluorescence values greater than those of cell-only controls (Figure 
11A), we were able to quantitate the proportion of cells with virions associated by 
flow cytometry analysis of the measured EGFP fluorescence.  Because cells 
may naturally express some level of autofluorescence (which we found to be well 
described by a log-normal distribution), we were careful to account for this 
background fluorescence in our analyses. With this in mind, we modeled the 
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fluorescence intensity profiles of inoculated cells as the sum of two log-normal 
distributions – where the first log normal distribution represents the population of 
cells without virus (with a mean corresponding to the fit for the cell-only control) 
and the second log-normal represents cells with virions bound/internalized, which 
would display a higher mean fluorescence.  Representative fits for various 
MOPs are shown in Figure 11B and the diminishing proportion of cells without 
virus coinciding with the increasing MOP should be noted. 
The fraction of the cells with virus associated was then determined by 
comparing the relative contribution from each distribution in accordance with the 
following expression: 
ai LogN1+ (1- ai)LogN2 
We determined the reliability of this deconvolution according to the 
confidence intervals of the ai fit parameter.  Hence, the extent of virion-cell 
interactions were measured over a range of MOP values (Figure 12). With 
increasing MOP, we found that greater fractions of cells had virions 
bound/internalized, confirming that, as expected, all cells had associated virions 
at high MOP.  
Normalizing the fraction of cells that became infected, as quantitated by 
replicate samples that were stained for β-galactosidase activity after 2 days of 
incubation (Figure 10) according to the proportion of cells with associated virions 
immediately following inoculation (Figure 12), we determined the relative 
infection efficiency (shown as an overlain curve in Figure 12).  Under these 
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conditions, we again observed that the infection efficiency continued to rise with 
increasing MOP.   However, we did note any significant impact on the 
experimentally-determined infection efficiency, which still differed a great deal 
from the projected values at high MOP (Table 5).  In fact, this observed infection 
efficiency continues to demonstrate that, even under conditions where there are 
large numbers of virions per cell, every cell will not actually become infected.    
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Figure 11  Representative Flow Cytometry Data 
 
Our data demonstrate that flow cytometry can distinguish the EGFP 
fluorescence of cells that have associated virions.  As shown in Panel (A), 
as the MOP increases, greater EGFP fluorescence values are observed vs. 
the cell only comparator (shown in gray).  Panel (B) demonstrates how the 
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EGFP fluorescence could be modeled according to the sum of two log-
normal distributions so that the relative contributions from the cell only 
population (blue line) and the cells with virions (red line) can be quantitated 
from the initial distribution of EGFP fluorescence (shown in black).  The 
increase in EGFP fluorescence resulting from the presence of cell-
associated virions can again be seen by comparing the sample distribution 
(in black) to a cell only comparator (shown in gray).   
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Figure 12  Infection Efficiency from Fraction of Cells with Associated 
Virions 
 
As determined by log-normal fitting of the EGFP fluorescence measured by 
flow cytometry, the blue columns represent the fraction of cells that were 
determined to have associated virions (either bound or internalized).  
Increasing fractions of cells with viruses are observed with greater MOP 
values.  The infection efficiency following virion attachment (shown in the 
black curve) was calculated as the ratio of the fraction of cells that became 
infected (Figure 10) to the fraction of cells with virions associated (blue 
bars).  The infection efficiency increases with MOP, but does not reach 
100% over this range of conditions.  Displayed values were determined by 
log-normal fitting of the EGFP fluorescence measured by flow cytometry of 
at least 103 cells ± SD (calculated from confidence interval of log-normal fit 
parameter, ai).  
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Table 5  Infection Efficiency Relative to Proportion of Cells with Virus 
Interactions  
 
Comparison of the projected fraction of cells to become infected (Expected 
column) and the experimentally measured fraction of cells to become 
infected relative to the proportion of cells with associated virions 
(Observed Column) demonstrates that MOP influences infection efficiency.   
Expected values were projected according to the calculated infectivity 
(infectious titer normalized to p24) at an MOP of 12.  Observed values 
represent the mean ± SE of 2 repeat samples. 
 
 
HIV Associates with Cells in a Proportionally-Consistent Manner 
In considering possible explanations for lower infection efficiency at high 
MOP, we pondered the likelihood that every virus particle associates with a cell.  
Although our flow cytometry analysis demonstrated that, at high MOP values, all 
cells have virions bound, it could be that only a few virions were actually binding 
to each cell.  So we re-examined our flow cytometry data to compare the 
relative increase (vs. cell-only controls) in the mean fluorescence intensities as a 
readout of the degree to which virions associated with cells.   The linear 
increase in EGFP fluorescence (Figure 13A) as a function of MOP is consistent 
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with the presence of more virion particles at higher MOP values.  This again 
suggests that the ability to associate with a host cell is not a significant factor in 
our observed limit to HIV-1 infection efficiency.  We also confirmed this 
observation using p24 ELISA to quantitate the number of virions that remained in 
solution after our 2hr inoculation.  Over the range of MOP values, we 
consistently found that nearly half (statistical mean 49.1 ± 8.9%) of the original 
inoculum remained in solution (Figure 13B).  The accordance in this 
measurement of the fraction of the inoculum remaining in solution across a range 
of MOP conditions indicates that the MOP-dependent infection efficiency is not 
significantly impacted by a virion’s ability to generally associate with a host cell.  
Hence, this consistency validates the rationality of the expected infection 
efficiencies (Table 4 and Table 5) because they are projected from observations 
under the same experimental conditions and, as such, are inherently normalized 
by the fraction of the inoculum associated with cells within 2 hours.   
As our studies did include DEAE dextran, however, we also needed to 
rule out the possibility that our observations might be influenced by the presence 
of this polycation.  A comparison of the extent of virus binding in the presence 
and absence of dextran (Figure 14) confirmed that the efficiency of virus and cell 
interactions was not significantly impacted, which is consistent with previous 
reports that DEAE dextran does not influence initial HIV-1 attachment onto cells 
[36].   
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Thus, under our experimental conditions, which involve constant rocking; 
and therefore, could potentially minimize the distance between virus particles and 
target cells, HIV-1 appears to associate with host cells in a proportionally-
consistent manner.  Furthermore, although commonly modeled as independent 
events, our data suggests that HIV-1 interactions with a target cell are in fact, 
influenced to some extent by the presence of other virus particles.  
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Figure 13  Consistent Proportions of Virion Inoculum Associate with Cells 
 
Panel (A) presents the increase in the mean fluorescence intensity (∆MFI) 
of cells inoculated with EGFP-tagged virions vs. cell-only controls as a 
function of MOP.  The linear fit (for which the Adjusted R2 value is listed in 
the figure) is consistent with the presence of more virion particles at higher 
MOP values. Data represent analysis of at least 103 cells.  The mean p24 
ELISA data from 2 repeat samples in Panel (B) indicates that the proportion 
of virus remaining in solution (relative to the original inoculum) is 
independent of MOP.  Therefore, the ability to generally associate with a 
host cell does not appear to be a significant factor in the observed MOP-
dependent limit to HIV-1 infection because, over the range of MOPs, the 
proportion of the inoculum associating with cells is consistent.   
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Figure 14  Presence of DEAE Dextran Does Not Significantly Impact the 
Extent of Cells with Associated Virions 
As quantitated via flow cytometry, the fraction of cells with associated HIV-
1 in the presence of 20 mg/ml DEAE dextran (open, black circles) is 
comparable to that cells inoculated in the absence of DEAE dextran (filled, 
red circles).  Displayed values were determined by log-normal fitting of the 
EGFP fluorescence measured by flow cytometry of at least 102 cells ± SD 
(calculated from confidence interval of log-normal fit parameter, ai). The 
data support the hypothesis that, under our experimental conditions, 
DEAE-dextran is not influencing the extent of cells with associated virions. 
 
Discussion 
The infectivity of cell-free HIV-1 is consistently reported to be less than 0.1% but 
there is not a clear understanding of why HIV-1 possesses such low infectivity.  
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In order to gain more knowledge about the factors influencing HIV-1 infectivity, 
we first sought to quantitate the overall efficiency of infection.  We were able to 
quantitate the overall infection efficiency by determining the fraction of cells that 
became infected following inoculation with a known amount of HIV-1 (Figure 
10A).  In fact, by varying the ratio between the number of HIV-1 particles 
(determined by p24 ELISA) and the number of potential CD4+ target cells, we 
quantitated the proportion of infected cells over a range of clinically-relevant 
multiplicity of particle (MOP) conditions.   The linear slope in the low MOP 
regime (Figure 10B) coincided with an overall infection efficiency of 
approximately, 0.023%.  However, the infection efficiency at high MOP (Figure 
10C), was lower - indicating that virion infectivity can be influenced by factors that 
may become more prominent at high MOP values.  
The low infectivity of retroviruses like HIV-1 has long been purported to 
be associated with the presence of defective virions [25], but there is a great deal 
of evidence suggesting that one of the primary limitations in the establishment of 
a productive HIV-1 infection is engaging and/or entering a target cell.  We 
hypothesized that, if the apparently low infectivity is a result of the inefficient 
manner by which virions find suitable targets, HIV-1 could actually be more 
infectious than reported.  Thus, we began to explore the molecular mechanisms 
underlying the virus’ low infectivity in order to elucidate the rate-limiting step in 
the HIV-1 infection process.  HIV-1 infection is a multi-step process and 
because we predicted that target cell engagement to have major influence on the 
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efficiency of infection, we calculated the overall efficiency of HIV-1 infection 
(Table 4) as well as the efficiency of infection following attachment (Table 5) in 
order to demonstrate whether associating with a host cell poses a significant 
limitation.   As described herein, we proceeded to quantitate virus and cell 
interactions through flow cytometry analyses of fluorescently-tagged HIV-1.  Our 
results demonstrated that HIV-1 is capable of interacting with cells in an efficient 
manner, such that the majority of cells still have detectable amount of virions 
associated with them at the conclusion of the 2 hour inoculation (Figure 11).   In 
fact, there was a linear increase in the EGFP fluorescence as a function of MOP, 
confirming that more fluorescently-tagged virions were interacted with cells at 
higher MOP values (Figure 13).  A comparison of the extent of virus binding in 
the presence and absence of dextran (Figure 14) confirmed that the efficiency of 
virus and cell interactions was not significantly impacted, which ruled out the 
possibility that our observations were influenced by the presence of this 
polycation.  Together, these findings suggest that the ability to attach to a 
potential target cell does not represent a significant limitation to HIV-1 infection.     
By using TZM-bl cells, we were able to conduct a side-by-side 
comparison of virion binding and the resulting infection in order to determine the 
efficiency of HIV-1 infection.  In reporting our findings, however, we realize that 
the observed nature of virion and cell interactions could possibly be influenced by 
cell-specific properties – e.g., receptor density or distribution, composition of the 
membrane, presence of host proteins, etc.  Ultimately, to elucidate any cell-line 
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dependence, similar studies will need to be conducted in other cell types.  With 
this in mind, one limitation to the interpretation of the results described herein 
pertains to the fact that TZM-bl cells are not natural targets of HIV-1 infection.  
Nevertheless, TZM-bl cells are widely used as targets to study HIV-1 infection.    
Conclusion 
We have quantitated the infection efficiency of HIV-1 and confirmed that, 
even under conditions where there are large numbers of virions per cell, such 
interactions will not always result in infection.  On the contrary, our data show 
that the productivity of virion-cell interactions is significantly limited by high MOP 
conditions.  These results suggest that the efficiency of HIV-1 infection changes 
according to HIV/AIDS disease progression, as viral loads increase and CD4+ T 
cells are depleted.  Thus, this finding offers unique perspective for 
understanding HIV-1 infection efficiency and highlights considerations of clinical 
import. 
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CHAPTER 4 
 
ENVELOPE-DEPENDENCE OF HIV-1 BINDING AND INFECTION 
 
Abstract 
HIV-1 particles are estimated to possess an average of only 14 envelope 
spike proteins [43] and by investigating the molecular mechanisms underlying 
virion attachment, we report evidence that the lack of binding to host cells via 
receptor-specific interactions poses a significant limitation in the virus’ ability to 
establish infection.  Specifically, utilizing fluorescent techniques we have 
gathered data showing that receptor-independent, virus-cell interactions correlate 
with lysosomal degradation of virions, indicating the fate of virions that are 
nonspecifically endocytosed.    
Introduction 
Productive human immunodeficiency virus type 1 (HIV-1) infection is 
believed to be initiated via interactions with cell surface receptors such as CD4, 
which is the primary receptor recognized by the virus, in conjunction with
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coexpressed chemokine co-receptors, CXCR4 and/or CCR5, which are 
necessary to facilitate membrane fusion [17] [18] [19] [20] [21].   Although the 
interactions between HIV-1 envelope glycoproteins and target cell receptors have 
been studied extensively, there are still several questions pertaining to the early 
events in HIV infection and how efficiently these receptor binding events result in 
productive infections. Indeed, it has been reported that the virus particles rapidly 
dissociate from target cells in culture, which can significantly influence the 
observed infectivity [36].   However, the molecular mechanisms underlying 
these transient interactions and/or the observed low infectivity have yet to be 
well-documented.   
Previously, we found that a high multiplicity of virus particles (MOP) limits 
the apparent efficiency of HIV-1 infection and demonstrated that the infectivity of 
HIV-1 could be enhanced with more envelope expression.  As these findings are 
consistent with the report that HIV-1 only expresses an average of 14 envelope 
spike proteins [43], we have sought to closely investigate the envelope-
dependence of HIV-1 binding and infection.   
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Materials and Methods 
Production of single-cycle HIV-1 virions. 
Virions were produced by transfecting HEK 293T/17 cells (ATCC, 
Manassas, VA) as previously described [54]. Briefly, 293T were cultured at 37oC 
with 5% CO2 in DMEM supplemented with 10% FBS (HyClone Laboratories, 
Logan, UT) and transfected at the fifth passage. 106 293T cells were seeded 
overnight in a T-75 flask with 10ml of culture media.  Using the TransIT LT-1 
transfection reagent (MirusBio, Madison, WI), HIV virions carrying free EGFP 
were generated by transfection with 4.0µg pNL4-3E- plasmid, 4.0µg pNL4-3E-
MA-EGFP-CA plasmid and 0.8µg pcDNA3.1REC.   After 6 hours of incubation 
at 37oC, the culture media (with transfection reagents) was removed and 
replaced with 16ml of fresh culture media.  The 37oC incubation continued for 
an additional 12 hour period.  At 18 hours post transfection, the culture media, 
containing EGFP-labeled single-cycle virions was collected and filtered through a 
0.45-mm syringe filter (Millex-HV PVDF, Millipore).  The filtrate was then 
aliquoted on ice, flash-frozen in a dry ice/ ethanol bath and stored in a -80oC 
freezer.  Subsequent analysis using p24 ELISA (HIV-1 p24 Antigen Capture Kit, 
Advanced Bioscience Laboratories, Rockville, MD) was conducted to determine 
the number of virus particles in a specified volume, assuming 2,500 molecules of 
p24 per virion. 
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Infection assay in TZM-bl cell line. 
TZM-bl cells (cat#8129, NIH AIDS Research and Reference Reagent 
Program) were cultured at 37oC with 5% CO2 in DMEM supplemented with 10% 
FBS (HyClone Laboratories, Logan, UT).  Prior to tenth passage, TZM-bl cells 
were trypsinized, counted, sedimented by centrifugation at 1,000g for 5 minutes 
and resuspended in DEAE dextran (final concentration 20 mg/ml) and/or DMEM 
with 10% FBS.  EGFP-labeled HIV-1 particles were added to aliquots of TZM-bl 
cells in 1.5ul Eppendorf tubes up to a total volume representative of each MOP 
condition.  The virion and TZM-bl cell mixture was incubated in suspension on a 
fixed-speed nutator (Fisher Scientific) at 37oC for 2hrs.  Following the 2hr 
inoculation, samples were immediately placed on ice to halt the infection process.  
Samples were kept on ice/at 4oC and washed (i.e., centrifugation at 1,000g for 5 
minutes followed by resuspension) with DMEM containing 10% FBS three times 
to remove any unbound virions.  However, the supernatant from the first wash 
was collected and flash frozen for later analysis via p24 Antigen Capture Kit 
(Advanced Bioscience Laboratories, Rockville, MD) in accordance with the 
manufacturer’s instructions.  Following the washing step, 2 aliquots (containing 
approximately 8x104 cells) from the cell-virion samples were seeded in 1ml of  
DMEM with 10% FBS in 24-well plates.  The samples were further incubated at 
37oC with 5% CO2 for 2 days.  After 2 days of incubation, cells were fixed in 2% 
gluteraldehyde at room temperature for five minutes. Cells were then washed 
three times with PBS, and stained for 50 min at 37oC using cell staining solution 
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provided in the beta-galactosidase staining kit (Mirus Bio, Madison, WI).    Cells 
were washed three times with milliQ water and the number of blue cells in each 
well was counted using a 10X objective on a Nikon TS100-F inverted microscope. 
Flow cytometry and confocal microscopy analyses 
Following inoculation in suspension and after aliquots were taken for 
beta-galactosidase staining, the remaining TZM-bl cells were resuspended in 4% 
paraformaldehyde for 10 minutes at room temperature.  After fixation, the 
samples were washed (i.e., centrifugation at 1,000g for 5 minutes followed by 
resuspension) in PBS two times.  The samples were kept at 4oC until 
subsequent flow cytometry analysis (using BD FACSCanto II flow cytometer).  
The resulting measurements of fluorescence intensity were analyzed via original 
Matlab code, designed to fit data to the sum of two log-normal distributions. 
For confocal analyses:  After PBS washing step, 100-200ul aliquots of 
were seeded on PLL-coated coverslips in 24 well plates and stored at 4oC 
preceding preparation for confocal microscopy analysis.  Following 4oC storage 
for overnight (at a minimum), cell membranes were stained with 200ul of Cholera 
Toxin B-Alexa 555 conjugate (Item# C2284, Invitrogen) for 10 minutes at room 
temperature.  After staining, coverslips were washed in PBS and mounted face 
down in 3ul of VectaShield.  Confocal images were gathered using 250nm step 
size and 100X oil objective on Olympus FluoView 500 Laser Scanning Confocal 
Microscope. Confocal image stacks were analyzed via custom Matlab code to 
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detect cell membrane boundaries and unique EGFP virions in accordance with 
the intensity of the corresponding fluorescence signal. 
For lysosome colocalization:  Samples were prepared according to 
protocol for confocal analysis, except that 50nM concentration of LysoTracker 
Red (Item# L7528, Invitrogen) was included in the inoculum.  Control 
experiments were conducted to confirm that the presence of LysoTracker did not 
influence virus titer (data not shown).  Cell membrane staining was omitted but 
confocal images were gathered as described above.  The extent of lysosomal 
colocalization was determined via custom Matlab code that localized EGFP-
tagged virions and LysoTracker Red-stained compartments according to the 
intensity of the fluorescence signals.  The percentage of EGFP-fluorescence 
that overlapped with LysoTracker Red relative to the total amount of EGFP 
fluorescence, M1, was determined for each z-stack, independently.   
Colocalization was then computed for each set of images as the average of M1 
values for z-stacks where an appreciable amount of EGFP-labelled virus could 
be detected.   
Receptor inhibition studies 
Studies utilizing sCD4 (cat#7356, NIH AIDS Research and Reference 
Reagent Program)  and AMD3100 (Item #A5602, Sigma-Aldrich) as CD4 and 
CXCR4 antagonists, respectively, were conducted as described above with the 
following steps preceding the addition of EGFP-labeled HIV-1 particles to 
aliquoted TZM-bl cells for inoculation:  AMD3100 was added to aliquoted TZM-
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bl cells to a final concentration of 1ug/ml.  Treated TZM-bl cells were then 
incubated in suspension on a nutator at 37oC for 1hr.  Meanwhile, sCD4 was 
added to aliquots of EGFP HIV-1 particles (in 1.5ml Eppendorf tube or 15ml 
conical tube, if experiment required larger volumes) to a final concentration of 
0.015 ug/ul.  The virus-sCD4 mixture was incubated on a nutator at 37oC for 1hr.  
Following pretreatment with AMD3100, TZM-bl cells were sedimented by 
centrifugation at 1,000g for 5 minutes and resuspended in DEAE dextran (final 
concentration 20 mg/ml) and/or DMEM with 10% FBS.  Appropriate volumes of 
the sCD4 - HIV-1 particle mixture and/or DMEM with 10% FBS were added to 
aliquots of TZM-bl cells in 1.5ul Eppendorf tubes up to a total volume 
representative of each MOP condition. 
Results 
Herein we demonstrate that the majority of all virus-cell interactions are 
due to nonspecific, receptor- and envelope-independent binding.  This 
nonspecific binding was found to significantly hinder the efficiency of HIV-1 
infection.  Furthermore, our data show that the extent of these non-specific 
interactions increases in accordance with the MOP – providing a mechanistic 
explanation for the inefficiency of HIV-1 infection at high virus concentrations.   
Non-specific Binding Accounts for the Majority of Virion-Cell Interactions  
Given that HIV-1 particles are estimated to possess an average of only 
14 envelope spike proteins [43], the likelihood to specifically engaging the 
required CD4 and chemokine receptors could be limited - giving rise more non-
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specific, receptor –independent binding/internalization.  In fact, it seems very 
plausible that any such inefficient/non-productive virus-cell interactions could 
result in an “apparent” infection efficiency that is lower than expected - 
particularly at high MOP conditions where receptor could potential be 
occupied/obstructed by other virions, consistent with our previous findings.  So 
we initiated a study to investigate the receptor-dependence of virion-cell 
interactions.   
Indeed, we discovered that, in the presence of sCD4 and AMD3100 (to 
inhibit envelope-mediated interactions with both CD4 and CXCR4 receptors 
respectively), the extent of virion-cell interactions still continued to increase with 
MOP (Figure 15A), even though no infection events occurred (data not shown).  
In fact, at high MOP values, nearly all virion-cell interactions could be attributed 
to this receptor-independent, non-specific binding pathway.  We confirmed this 
observation by conducting similar analyses with virus-like particles lacking HIV-1 
envelope proteins.  In this case, we observed that the extent of virion-cell 
interactions were comparable to the non-specific binding observed in our 
experiments with single-cycle HIV-1 (see Figure 15B for comparison).   Thus, 
our data support the notion that, at least under our experimental conditions, non-
specific binding accounts for the majority of all virion-cell interactions, the exact 
proportion of which increases with MOP. 
Given that, at least in our experimental conditions, non-specific virion-cell 
interactions appeared to represent the majority of all virion-cell interactions, we 
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decided to study the fate of those virions that interact with cells in a receptor-
independent manner.  It has previously been shown that HeLa-derived cells can 
internalize NL4-3∆Env, virus-like-particles non-specifically via endocytosis [68].   
Furthermore, the same study indicated that up to 90% of intracellular NL4-3 was 
internalized via endocytosis, with a large majority resulting in lysosomal 
degradation.  Therefore, we conducted similar analyses to characterize non-
specific, receptor-independent virion-cell interactions under our experimental 
conditions.  First, to elucidate the proportion of virions that are surface-bound vs. 
internalized, we used confocal imaging to analyze the distribution of virions 
relative to the cell membrane (see representative image in Figure 16A).  We 
utilized a custom Matlab code to detect the position of EGFP-labeled virions 
according to the intensity of the fluorescence signal and pinpoint the virions’ 
location relative to the boundaries of the cell membrane.  Our analyses revealed 
that, consistent with previous reports, an average of approximately 86% of cell-
associated virions are internalized (Figure 16B, blue bars).  In the presence of 
inhibitory concentrations of sCD4 and AMD3100, we observed that the proportion 
of cell-associated virions remains relatively unchanged (Figure 16B, red bars).  
Interestingly, these relative intracellular distributions were independent of MOP.  
This result, which is consistent with our flow cytometry data, reveals that the 
majority of virus-cell interactions are mediated in a receptor-independent fashion 
that results in some form of endocytosis.
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Figure 15  Non-specific Binding Accounts for the Majority of Virion-Cell 
Interactions 
 
The extent of HIV receptor-independent cell interactions were quantitated 
via flow cytometry.  Analysis of the fraction of cells with associated 
virions in the presence of CD4 and CXCR4 antagonists (sCD4 and 
AMD3100, respectively) is shown in Panel (A).  The fraction of cells with 
associated virions in the absence (blue bars) or presence of both inhibitors 
(red bars) are shown for direct comparison.  Under our experimental 
conditions, the data suggest that non-specific binding/internalization may 
account for a large portion (at least 86%) of all HIV-1 interactions with a 
target cell. Displayed values were determined by log-normal fitting (as 
deduced from the sum of 2 log-normal distributions) of the EGFP 
fluorescence measured by flow cytometric measurements of at least 102 
cells ± SD (calculated from confidence interval of log-normal fit parameter, 
A 
B 
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ai).  As shown in Panel (B), the extent of virion-cell interactions for single-
cycle HIV-1 (open, black circles) is comparable to that of virus-like particles 
lacking HIV-1 envelope proteins (filled, red circles).  Thus, the data provide 
further evidence that non-specific binding accounts for the majority of all 
virion-cell interactions under our experimental conditions. 
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Figure 16  Distribution of Cell-Associated Virions 
 
 
Three-dimensional, confocal analysis was utilized to study the distribution 
of cell-associated virions.  A representative confocal image at MOP of 
1203 is shown in Panel (A).  EGFP-labeled virions (green particles) can be 
seen relative to the cell membrane, which has been stained red using 
cholera Toxin B-Alexa 555 conjugate.  As determined by confocal image 
analysis, an average of approximately 86% of cell-associated virions are 
internalized (blue bars, Panel (B)).  In the presence of inhibitory 
concentrations of sCD4 and AMD3100, the proportion of cell-associated 
virions remains relatively unchanged (red bars).  The relative intracellular 
distributions were consistent across a wide range of MOP values.  Data in 
B 
A 
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Panel (B) are representative of the mean percentage ± SE for at least 3 
replicate images at each MOP.   
 
Non-specific Binding is Associated with Virion Degradation 
Since there were no productive infections for experiments conducted in 
the presence of sCD4 and AMD3100, we sought to examine the fate of 
internalized virions in the presence and absence of receptor antagonists to 
determine whether virions that were internalized via receptor-independent 
mechanisms would be degraded in the lysosomes.  We anticipated detecting an 
increase in virion colocalization with lysosomal compartments as a result of sCD4 
and AMD3100 pre-treatment. And so, to test this hypothesis, we labeled late 
endosomes/lysosomes with the membrane-penetrating stain, LysoTracker Red.  
As shown in Figure 17, we were only able to detect a small percentage of virions 
colocalizing to these acidic compartments overall.  This was expected given that 
substantial lysosomal degradation had probably occurred prior to the end of our 
2-hour inoculation period.  Nevertheless, we did observe distinct behaviors 
between the low MOP and high MOP regimes. While we originally observed very 
little colocalization at an MOP of 61, the addition of CD4 and CXCR4 antagonists 
(Figure 17, red bars) led to an increase in the degree of colocalization.  At 
higher MOP values, however, the addition of receptor antagonists did not result 
in a significant change – as there was already a detectable amount of 
colocalization in the absence of such inhibitors.  Thus, collectively our data 
suggest that, for low MOP conditions, inducing non-specific, receptor-
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independent endocytosis results in more virion degradation.  Interestingly, at 
high MOP, the extent of virion degradation is greater (vs. low MOP in the 
absence of receptor antagonists) and remains unaffected by the inhibition of 
receptor-mediated interactions.   This observation is consistent with our other 
data and suggests that there is already a good deal of virion degradation at high 
MOP conditions, as a result of the predominant receptor-independent 
interactions with the cell. 
Based on these observations, we sought to quantitate the proportion of 
“specific”, receptor-dependent binding as the relative difference between the 
fraction of cells with virions associated in the absence of inhibitors and the 
fraction of cells with virions associated in the presence of receptor inhibitors.  
Recalculating the infection efficiency based on this fraction of cells with virions 
specifically bound, could therefore, result in a quantitative measure of the true 
infection efficiency of HIV-1.  Under our experimental conditions, however, the 
extent of specific binding could only be reliably quantitated for MOP values in a 
narrow range (i.e., 30<MOP<240).  In these experiments (Figure 15, Figure 16, 
and Figure 17), the uncertainty in the EGFP fluorescence fit parameters 
suggested that the extent of binding at MOP<30, may be too low to distinguish – 
which is expected given that the change in mean fluorescence intensity is likely 
to be small.  On the contrary, at high MOP values, nearly all cells have virions 
bound – even in the presence of receptor antagonists, making it difficult to 
distinguish receptor-specific binding. In fact, only at MOP of 61, was the extent of 
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virion-cell interactions in the presence of sCD4 and AMD3100 determined to 
potentially be significantly different from the extent of virion-cell interactions in the 
absence of these CD4 and CXCR4 antagonists.  Therefore, based on our 
experimental observations at an MOP of 61, we determined that HIV-1 infects 
cells via receptor-mediated binding with an “inherent” efficiency of approximately 
19% - a number that is comparable to the 13% infection efficiency previously 
reported for VSV-G pseudotyped HIV and 5 times greater than the observed 
“apparent” infection efficiency from prior studies.  Thus, our results consistently 
demonstrate that the inability to initiate and/or sustain receptor-specific 
interactions with a target cell significantly hinders the efficiency of HIV-1 infection.
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Figure 17  Virion Colocalization with Lysosomes 
 
The extent of virion colocalization with late endosomes/lysosomes was 
determined by confocal imaging in the presence and absence of sCD4 and 
CXCR4 inhibitors (red bars and blue bars, respectively).  Data are 
representative of the mean percentage ± SE for at least 3 replicate images 
at each MOP. 
 
Envelope Expression Correlates with Specific Binding 
Our data consistently point toward the importance of specific binding between 
HIV-1 envelope glycoproteins and target cell receptors and since we previously 
demonstrated that the infectivity of HIV-1 could be enhanced with more envelope 
expression, we sought to quantitate the extent of envelope-dependent, specific 
binding among virions engineered to express a higher density of envelope spike 
proteins.  Specifically, using flow cytometry, we quantitated the relative 
difference between the extent of virion-cell interactions in the absence of sCD4 
and AMD3100 and the fraction of cells interacting with virions in the presence of 
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these receptor antagonists.  As shown in Figure 18, the results indicate that the 
increase in envelope expression also leads to a greater fraction of specific 
binding.  When considered in light of our prior observations and the correlation 
between greater infectivity and more envelope protein expression, these data 
provide additional evidence of how envelope-mediated mechanisms influence 
HIV-1 binding, internalization, and overall infectivity.  
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Figure 18  Receptor-Specific Binding Correlates with Envelope Expression 
 
Data demonstrate the extent of receptor-dependent, specific binding, 
quantitated as the relative difference between the fraction of cells 
interacting with virions in the absence of inhibitors and the fraction of cells 
interacting with virions in the presence of receptor inhibitors for virus with 
variable amount of envelope at MOP=61.  The fractions of cells interacting 
with virus were determined by log-normal fitting of the EGFP fluorescence 
measured by flow cytometry of at least 103 cells ± SD (as calculated from 
confidence interval of log-normal fit parameter, ai, for a control sample).  
These data suggest that increased envelope expression results in a greater 
proportion of specific binding, which is consistent with our previous 
finding that infectivity increases with envelope expression. 
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Discussion 
Although our initial studies of the limitations in the establishment of a 
productive HIV-1 infection did not reveal significant influence/inefficiency due to 
the inability of virions to interact/associate with cells, we pursued additional 
experiments in order to fully investigate whether binding might influence the 
efficiency of HIV-1 infection in manner that would be dependent on the effective 
virus concentration.   
Previous reports have demonstrated that HIV-1 is capable of interacting 
with cells in a receptor-independent manner.  Non-specific interactions mediated 
by lectins like DC-SIGN on dendritic cells [69] or adhesion molecules such as 
ICAM-1 [30] have been well-described.  Indeed, the presence of heparan sulfate 
proteoglycans on HeLa-derived cells has also been noted to play a role in virion 
attachment [70].  Therefore, we decided to characterize the nature of virion-cell 
interactions at a molecular level in order to determine the receptor-dependence 
under our experimental conditions.  We quantitated the extent of virion-cell 
attachment occurring in the presence of inhibitory concentrations of CD4 and 
CXCR4 antagonists (Figure 15A) and in comparison to virus-like-particles lacking 
envelope glycoproteins (Figure 15B).  Consistent with previous reports, we 
found that a large majority of virion interactions could be attributed to non-specific, 
receptor-independent attachments.  Interestingly, the extent of non-specific 
binding appeared to increase with MOP and nearly all virion-cell interactions at 
high MOP values could be characterized as non-specific.  Recalculating the 
78 
 
 
efficiency of HIV-1 infection according to the extent of specific interactions (which 
could only be determined in the low MOP regime), revealed that the efficiency of 
infection following specific binding is about 19%.  Hence, the results of our study 
confirm that the lack of binding to target cells in a receptor-specific manner 
significantly hinders HIV-1 infection and results in an infectivity that appears 
much lower than the virus’ inherent infectious capability.   
Our results also confirm previous reports that HIV-1 can be internalized 
via non-specific interactions.  In our experiments, we observed that 
approximately 89% of cell-associated HIV-1 resulting from receptor-independent 
uptake was detected inside of the cell.  Since, under our experimental 
conditions, which utilize single-cycle HIV-1 virions engineered (as described in 
Methods) to carry free molecules of enhanced green fluorescent proteins 
(EGFPs), we only expect to detect punctate EGFP fluorescence from intact 
virions.  Therefore, we can reasonably conclude that most, if not all, of these 
non-specifically internalized virions were taken up via some form of endocytosis 
as they appear as intact virions.  Indeed, our data align closely with the findings 
of Maréchal et al, who have previously reported that approximately 90% of 
virions entered HeLa-derived cells via non-specific vesicular uptake and that the 
majority of these internalized particles would be degraded in the lysosomes [68].   
Furthermore, although commonly modeled as independent events, our 
data suggests that HIV-1 interactions with a target cell are in fact, influenced to 
some extent by the presence of other virus particles.  Our work shows that the 
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extent of non-specific interactions between HIV-1 and target cells increases in 
accordance with the multiplicity of virus particles.  As the presence of other 
virions could impact the accessibility of receptors, we believe that this finding 
provides a reasonable explanation for the differences we observed a high MOP.  
In fact, at high MOP values, we observed that non-specific binding accounts for 
nearly all virion-cell interactions (Figure 15A) and the prevalence of this non-
specific binding coincides with a significant limitation in the observed infection 
efficiency (prior reports) as well as an increase in the amount of lysosomal 
targeting (Figure 17).  Therefore, the results of this study demonstrate that the 
inability to specifically engage the appropriate receptors on a target cell could 
potentially be influenced by the presence of other virus particles.     
Although the observed nature of virion and cell interactions could possibly 
be influenced by cell-specific properties, TZM-bl cells are widely used to study 
HIV-1 infection.   And because this HeLa-derived cell line has been genetically 
engineered to expresses high levels of CD4, CXCR4, and CCR5, there is still 
some broader relevance to our findings.  According to previous reports, TZM-bl 
cells are estimated to express an average of ~3x105 CD4 receptors and ~2x104 
CXCR4 co-receptors [71] [72], corresponding to nearly 10 times more CD4 and 3 
times more CXCR4 than CD4+ T cells in peripheral blood mononuclear cells 
(PBMC) obtained from patients [73].  Therefore, our demonstration of the lack of 
receptor-dependent binding, even when more receptor targets are present, is 
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significant for providing insight into the molecular mechanisms that may influence 
virus binding and ultimately, the efficiency of the infection process.   
Conclusion 
We have determined that nonspecific, receptor-independent binding interactions 
impose a significant limitation to HIV-1 infection efficiency. Although HIV-1 is 
capable of infecting with approximately 19% efficiency via receptor-specific 
binding, this infection efficiency is masked by nonspecific interactions with host 
cells, which become more prevalent at high MOP. Our data show that these 
receptor-independent interactions correlate with lysosomal degradation of virions, 
indicating the fate of virions that are nonspecifically endocytosed.  However, 
HIV-1 engineered to express a greater number of envelope spike proteins display 
more receptor-specific binding. Thus, we report that molecular binding 
mechanisms, which are significantly influenced by HIV-1 envelope expression, 
bear substantial impact on the apparently low infectivity of HIV-1.  
81 
 
 
 
CHAPTER 5 
 
BIOWAIVERS FOR COMBINATION DRUG PRODUCTS:  APPLYING A 
PROVISIONAL BCS CLASSIFICATION TO HIV ANTIRETROVIRAL 
PRODUCTS 
Abstract 
To motivate regulatory and scientific advancement with regard to 
requirements for bioequivalence, we have provisionally classified and assessed   
the biopharmaceutical properties of and 34 single-entity and 22 fixed-dose, co-
formulated, combination oral drug products in late stage clinical development 
(Phase 2 or beyond) or post-marketing phase for indications to treat the Human 
Immunodeficiency Virus (HIV).  For effective treatment against this deadly 
disease, HIV antiretroviral therapy combines the effect of multiple mechanisms of 
antiviral activity through co-administration of single-entity drug products or, when 
available, simpler administration of fixed-dose co-formulations.  As there is a 
significant unmet medical need for access to antiretroviral therapy globally, 
efforts to enable simplified and/or abridged development pathways may 
substantially improve the availability of these essential medicines.    
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Current regulatory guidelines permit waivers of in vivo bioequivalence 
studies for immediate-release orally administered products comprised of drug 
substances that are highly soluble, according to the Biopharmaceutical 
Classification System (BCS).  Our provisional assessment has revealed that 38% 
of the single-entity drug products and 36% of the co-formulated drug 
combinations are comprised of high solubility compounds and are, therefore, 
potentially eligible for BCS-based biowaivers under the existing regulatory 
framework.  In theory, however, in vitro data could be used to justify biowaivers, 
regardless of BCS classification.  Such a theoretical opportunity is especially 
relevant to the development  of fixed-dose combinations of single-entity 
products that have an established safety and efficacy profile for co-administration, 
which is the case for many antiretroviral drug products because the otherwise 
required in vivo studies  analyzing each active moiety are inherently more 
complex, time consuming, and expensive.  Thus, this provisional assessment is 
intended to highlight opportunities to utilize scientifically-valid in vitro dissolution 
strategies to demonstrate bioequivalence between co-formulated drug products 
and the reference, single-entity products administered in combination. More 
broadly, as dissolution methodologies with in vivo relevancy are developed, in 
vitro assessments of bioequivalence may replace the complex in vivo studies 
currently required for drug combinations; and, as a result, lead to increased 
availability of more effective combination drug products, especially in developing 
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countries where such products can help address health care disparities and 
significant unmet medical need.  
Introduction 
Unique regulatory opportunities exist to reasonably enable formulation 
changes and refine or amend manufacturing processes for established drug 
products and to expedite the development of generic drug products by 
demonstrating bioequivalence in comparison to a reference product. For two 
drug products to be considered as bioequivalent they must be pharmaceutically 
equivalent (i.e., containing the same active pharmaceutical ingredient(s), or API, 
in the same dosage form and at the same strength for the same route of 
administration) or alternative (i.e., same therapeutic moiety as a different 
molecular entity or in a different dosage form or strength) and demonstrate 
comparable bioavailability [74].  Standard bioequivalence studies can be 
conducted in healthy volunteers by administering single doses of the test and 
reference drug products according to a two-treatment, crossover or a four-period, 
replicate crossover study design [74] [75].  In order to prove bioequivalence, 
statistical analyses should demonstrate that the critical pharmacokinetic 
parameters for: a) the extent  of absorption, most often determined by the area 
under the plasma concentration-time curve (AUC) for the last measured 
concentration (AUCT) and as extrapolated to infinity (AUCinf), as well as b) the 
rate  of absorption, as measured by the maximum drug concentration (Cmax) of 
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API from the test drug product are all ≥ 80.00% and ≤ 125.00% of the 
corresponding parameters for the API from the reference drug product.    
In some cases, alternate in vivo or in vitro methods may represent more 
reasonable and scientifically valid bioequivalence studies.  The 
Biopharmaceutical Classification System (BCS), a method that categorizes drugs 
according to their aqueous solubility and intestinal permeability, is one 
scientifically valid basis for justifying alternate bioequivalence approaches [76].   
Specifically, for some high-solubility drugs, where the in vivo dissolution is rapid 
relative to the gastric emptying time, regulatory authorities have determined that, 
when certain criteria are satisfied, in vitro dissolution studies can be used to 
demonstrate bioequivalence. The European Medicines Agency (EMA)’s 
Committee for Medicinal Products for Human Use (CHMP) scientific guidelines, 
for example, state that satisfactory in vitro data will be accepted in place of in 
vivo bioequivalence studies for immediate release, oral drug products where the 
drug substance exhibits high solubility and complete absorption (BCS Class I), if 
both the test and reference products demonstrate in vitro dissolution 
characteristics of more than 85% dissolution within 30 minutes (similarly rapid) or 
15 minutes (very rapid) and inactive ingredients potentially affecting 
bioavailability are qualitatively and quantitatively the same [75].  Similarly, EMA 
also permits BCS-based biowaivers when the drug substance exhibits high 
solubility and limited absorption (BCS Class III) if the in vitro dissolution profiles 
of the test and reference products show very rapid dissolution and there are no 
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qualitative or quantitative differences in excipients that may affect bioavailability.   
The United States Food and Drug Administration (FDA) also allows BCS-based 
waivers from in vivo bioequivalence studies for immediate-release solid oral 
dosage forms containing BCS Class I drug substances, if the excipients do not 
significantly affect absorption. Specifically, the FDA has indicated that biowaivers 
for the demonstration of in vivo bioavailability may be justified for a BCS Class I 
drug substance in an immediate release oral dosage form that exhibits rapid in 
vitro dissolution resulting in at least 85% of the drug substance dissolving within 
30 minutes using the recommended test [77]. The FDA guidance on biowaivers 
for BCS Class I drugs has been established since 2000 and it was not until 
fifteen years later that the FDA issued new draft guidance extending the option 
for biowaivers to BCS Class III drugs [78].  The FDA and EMA note several 
additional factors that must be considered for determining the suitability of a 
BCS-based biowaiver and both agencies exclude drugs with narrow therapeutic 
ranges as well as drug products absorbed in the oral cavity, such as sublingual 
or buccal formulations.  
 For fixed dose combinations, when multiple active ingredients are 
present together in the same dosage form, demonstrating bioequivalence 
becomes more complex, as each API must demonstrate comparable 
bioavailability, and the scientific rationale for utilizing alternate and/or in vitro 
dissolution methods is especially important.  Theoretically, a well-designed, oral 
fixed-dose combination drug product, formulated with individual drugs that exhibit 
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linear and non-interacting ADME, in the absence of excipients that significantly 
affect bioavailability, should have the same in vivo dissolution characteristics and 
hence absorption profiles as the constituent, single-entity drug products in the 
same dosage form, and, as a result, will be bioequivalent, regardless of BCS 
classification. However, to-date there is not a regulatory pathway for applying 
biowaivers to products containing BCS Class II or BCS Class IV drugs as the 
single active ingredients; thus, there is no existing basis for extending biowaivers 
to fixed dose combinations of BCS Class II or IV drugs that are already 
established as single-entity drug products that are co-administered in a 
comparable dosage form.    
The EMA has determined that there is sufficient rationale for extending 
biowaivers to combinations of BCS Class I and/or Class III drugs.  In Europe, 
BCS-based biowaivers are applicable for immediate-release, fixed-dose 
combination drug products if all of the active substances are BCS Class I or BCS 
Class III drugs, as long as the requirements regarding excipients are also 
satisfied [75].  The FDA recently incorporated a similar approach into their 2015 
draft guidance, which documents a new pathway for applying BCS-based 
biowaivers to immediate-release fixed-dose combination drug products where all 
of the active substances are BCS Class I.  If the excipients in the test product 
are the same as those in the reference product, the FDA’s draft guidance also 
extends the regulatory pathway to fixed dose combinations where all of the active 
87 
 
 
constituents belong to BCS Class III or represent a combination of BCS Class I 
and Class III drugs [78].  
The 2015 draft guidance represented major regulatory progress as, up 
until this time, the opportunities for BCS-based biowaivers in the U.S. were more 
limited than those in Europe. In fact, prior to the general guidance issued by the 
FDA in 2015, it was essentially unclear whether the FDA would grant biowaivers 
for fixed dose combinations.  For example, there was no mention of biowaivers 
within the FDA’s 2006 Guidance for Industry, Fixed Dose Combinations, Co-
Packaged Drug Products, and Single-Entity Versions of Previously Approved 
Antiretrovirals for the Treatment of HIV. On the contrary, the 2006 FDA guidance 
merely stated that it was necessary to show that the rate and extent of absorption 
of each active constituent of the test, fixed dose antiretroviral combination are the 
same as those for each component of the reference drug combination [79].  Yet, 
given the chronic nature of HIV infection and the need for strict patient 
compliance in order to minimize the chances of emerging viral resistance [44], 
fixed dose combinations are commonly utilized for more convenient and 
simplified dosing regimens, which may result in greater levels of patient 
compliance. Several studies have demonstrated that, when compared to 
regimens requiring multiple tablets, single-tablet HIV regimens are associated 
with greater adherence; and as a result, lead to more viral suppression [45] [46] 
[47].  The current U.S. Department of Health and Human Services (HHS) HIV 
treatment guidelines recommend starting treatment with a regimen of three HIV 
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medicines from at least two different drug classes among non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors 
(NRTIs), protease inhibitors (PIs), fusion inhibitors, entry inhibitors, and integrase 
strand transfer inhibitors (INSTIs).  In general, the treatment guidelines 
recommend that patients naïve to antiretroviral therapy initiate therapy with a 
regimen that includes two NRTIs in combination with an NNRTI, a PI boosted 
with a pharmacokinetic enhancer, or an INSTI [37].  Because of the clinical 
basis for utilizing several drugs in combination, and the wide array of established 
single-drug products that are co-administered [79], antiretrovirals represent a 
therapeutic class of drug products where an expanded regulatory framework for 
applying biowaivers of in vivo bioequivalence studies, is germane to the ability to 
effectively address the significant global unmet medical need.   
The World Health Organization (WHO) reports that HIV is the world’s 
leading infectious killer, with approximately 39 million people having died from 
AIDS-related causes so far [5].  There are currently about 35 million people 
living with HIV [8].  While the large majority of the people living with the virus 
reside in low-/middle- income countries [80] [81], only 36% of the population 
eligible for therapy under the WHO treatment guidelines [82] is receiving 
antiretroviral therapy in these regions [5].  And of the 3.2 million children 
infected with HIV globally, only 23% have access to treatment [83].  Thus, within 
the context of this disease alone, the increased availability of therapeutically 
equivalent drug products and co-formulated combination drug products can have 
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a tremendous impact on improving public health worldwide.  Reducing the 
clinical burden, by creating a framework for the acceptability of in vitro data in 
place of in vivo bioequivalence data, will likely promote competition and enable 
additional products to enter the market from sources that may have been 
deterred by the costs and timelines associated with human studies [84].  
As a result of recognizing the potential impact, many global health 
organizations and advocates have noted the importance of facilitating the 
development of pharmaceutically and/or therapeutically equivalent products from 
multiple sources in order to address global pandemics such as HIV/AIDS.  The 
Prequalification Programme administered by the WHO, for example, was 
established in 2001 to help facilitate access to products designed to treat priority 
diseases, including HIV/AIDS.  The Prequalification Programme helps address 
treatment gaps in countries that otherwise have limited access to quality 
medicines by prequalifying medicinal products that meet certain standards for 
safety, efficacy, and quality as acceptable for procurement by United Nations 
organizations, including the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), United Nations Children’s Fund (UNICEF) and United Nations 
Population Fund (UNFPA).  Any manufacturer (innovator or generic) can apply 
for prequalification to supply products that are listed on the WHO’s Invitation for 
Expression of Interest.  If the WHO assessment demonstrates that the product, 
manufacturing facilities, and clinical sites all meet the WHO’s standards, the 
sponsor’s product will be included on the list of prequalified medicines for 
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procurement.  The WHO assessment teams include experts from stringent 
regulatory authorities (such as SwissMedic, Health Canada, and national 
regulatory authorities within the European Union) who partner with regulators 
from the developing countries where the products will be utilized to complete the 
assessment.  Both single-entity drug products and fixed dose combinations are 
eligible for prequalification.  The WHO has been implementing BCS-based 
biowaivers since 2008 and their principles for assessing for fixed dose 
combinations are intended to align with those of the EMA and FDA.  
Interestingly, the WHO Prequalification Programme actually specifies the drugs 
that are currently eligible for BCS-based biowaivers and confirms that in vivo 
bioequivalence data are required for fixed dose combination containing any other 
APIs [85].  
Realizing the potential for global impact and the need to motivate even 
more scientific advancement with regard to requirements for bioequivalence, we 
have conducted a provisional assessment of the biopharmaceutical properties of 
established and investigational antiretroviral drug products for the treatment of 
HIV infection.  The results of our assessment can serve as the starting point for 
developing product-specific scientific rationale to potentially simplify and 
accelerate the development and availability of co-formulated antiretroviral drug 
products globally – especially in developing countries, where there is a significant 
unmet medical need.   
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Materials and Methods 
Drug Lists 
Lists of drug products approved (i.e., in the post-marketing phase in the 
U.S., European Union, or Canada) and/or in development (Phase 2 and beyond) 
for an HIV indication were obtained using clinical trial and literature review 
software/search engine sourced from public information. Only oral dosage forms 
were included.    The drug list was verified and refined by reviewing clinical trial 
information (www.clinicaltrials.gov), published scientific literature (when 
available), corporate press releases, and reference labeling approved by the 
FDA, EMA, and/or Health Canada.  The regulatory status of the drug products 
was determined by reviewing the FDA approvals as of December 4, 2014 
(www.fda.gov). 
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Solubility 
Solubility from Reference Literature.  The aqueous drug solubility 
values (mg/mL) were obtained from the product labeling approved by the FDA, 
EMA and/or Health Canada.  In cases where the aqueous solubility was 
described qualitatively, a conservative numerical value was assigned based on 
the lower limit of the range defined in the U.S. Pharmacopeia [86], in accordance 
with the methodology utilized by Kasim et al [87].  
When unavailable from reference literature, aqueous solubility values 
were determined using ChemDraw software (CambridgeSoft Corp., Cambridge, 
MA) or sourced from ALogPS 2.1, as reported via DrugBank (www.drugbank.ca).  
pKa values were obtained in similar fashion. 
Dose Number Calculations.  Per existing FDA guidance, the solubility 
class of a drug substance is based on the highest dose strength.  A drug is 
considered highly soluble when the highest dose strength is soluble in 250 ml or 
less of aqueous media over the pH range of 1-6.8 [78; 77].  The volume 
estimate of 250 ml is derived from typical BE study protocols that prescribe 
administration of a drug product to fasting human volunteers with a glass (about 
8 ounces) of water [78; 77].  
The dose number, a dimensionless solubility parameter normalized by 
dose, was calculated, in accordance with the method utilized by Dahan et al [88] 
for in silico BCS classification, as follows: 
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where M0 is the maximum dose strength (milligrams), Cs is either the solubility 
(milligrams per milliliter), and V0 = 250 mL.  Drugs where Do ≤ 1 were classified 
as high solubility and drugs with D0 > 1 were categorized as low solubility.  
Partition Coefficients 
In silico n-Octanol/water partition coefficients of the uncharged drug were 
determined from several different sources.  Calculations of Log P based on the 
chemical structure of the drug were obtained using ChemDraw software 
(CambridgeSoft Corp., Cambridge, MA). Log P values were also sourced from 
the ALogPS 2.1, as reported via DrugBank (www.drugbank.ca). Per the in silico 
methods utilized by Dahan et al, permeability was categorized in reference to 
metoprolol, as 95% of this compound is known to be absorbed from the 
gastrointestinal tract [89].  Accordingly, drugs with LogP values ≥ 1.632 were 
classified as high permeability and drugs with LogP values < 1.632 were 
categorized as low solubility.  
 
Results 
Mechanisms, Permeability, and Solubility of Single-Entity Antiretroviral Drug 
Products 
Thirty-four (34) drug products with a single API were identified as either 
being in late stage clinical development or in post-marketing phase for an HIV 
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indication. As listed in Table 6, 26% of these drugs products have yet to be 
registered or tentatively approved.  Consistent with treatment guidelines, which 
generally recommend nucleoside reverse transcriptase inhibitors as the 
backbone to an effective antiretroviral regimen in treatment-naïve patients, 
NRTIs represented the most common class among the single-entity drug 
products assessed, as the antiretroviral activity of 11 out of the 34 (i.e., 32%) can 
be attributed to this mechanism of action (Figure 19).  Only 12% represented 
novel or unconventional mechanisms of antiretroviral activity:  fusion inhibitors 
(3%), entry inhibitors (6%), or other mechanisms such as immunological boosting 
(3%).  
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Table 6  US Regulatory Status of HIV Indication for Single-Entity Drug 
Products 
Drug Name US Regulatory Status 
apricitabine Development 
cabotegravir Development 
cenicriviroc Development 
doravirine Development 
elvucitabine Development 
festinavir Development 
fostemsavir Development 
naltrexone Development 
tenofovir alafenamide Development 
darunavir Tentatively Approveda 
abacavir sulfate Approved 
amprenavir Approved 
atazanavir sulfate Approved 
cobicistat Approved 
delavirdine (mesylate) Approved 
didanosine Approved 
dolutegravir Approved 
efavirenz Approved 
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Table 6 Continued. 
Drug Name US Regulatory Status 
elvitegravir Approved 
emtricitabine Approved 
etravirine Approved 
fosamprenavir calcium Approved 
indinavir sulfate Approved 
lamivudine Approved 
maraviroc Approved 
nelfinavir mesylate Approved 
nevirapine Approved 
raltegravir potassium Approved 
rilpivirine hydrochloride Approved 
ritonavir Approved 
saquinavir mesylate Approved 
stavudine Approved 
tenofovir disoproxil fumarate Approved 
zidovudine Approved 
a Tentative approval indicates that final approval of the drug product has 
been delayed until resolution of all patent or exclusivity issues.  The product 
cannot be marketed or sold in the United States until final approval is granted.
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Figure 19  Antiretroviral Mechanism of Action for Single-Entity Drug 
Products 
 
 
Where: 
NNRTI  =  non-nucleoside reverse transcriptase inhibitor 
NRTI  =  nucleoside reverse transcriptase inhibitor  
PI  =  protease inhibitor 
INSTI = integrase strand transfer inhibitor 
Fusion = fusion inhibitor 
Entry = entry inhibitor
NNRTI
NRTIPI
Fusion
Entry INSTI
Other
PK Boost 
Only
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Table 7  Provisional Data for Single-Entity Drug Products 
Drug Name 
US Regulatory 
Status*   
(as of Dec 4 2014) 
Mechanism 
of Action 
Max 
Dose† 
(mg) 
Solubility 
Definition 
(from literature) 
For Do Calculation  Dose 
Number
(Do) 
Provisional 
BCS Class Solubility 
(mg/mL)  logP 
apricitabine  Development  NRTI  1600  ‐  0.65  ‐0.99  9.77  IV 
cabotegravir  Development  INSTI  60  ‐  0.00008  1.04  2952.65  IV 
cenicriviroc  Development  Entry  200  <0.0002  0.0002  7.5  4000  II 
doravirine  Development  NNRTI  100  ‐  0.000007  2.23  58487.09  II 
elvucitabine  Development  NRTI  10  ‐  13  ‐0.81  0.003  III 
festinavir  Development  NRTI  600  ‐  0.08  ‐0.08  28.79  IV 
fostemsavir  Development  Fusion  1200  ‐  0.00005  ‐0.18  101214.15  IV 
naltrexone  Development  Other  3  ‐  100  1.36  0.0001  III 
tenofovir alafenamide  Development  NRTI  25  ‐  0.00003  1.88  3213.66  II 
darunavir  Tentatively Approved  NRTI  800  ‐  0.15  2.82  21.33  II 
abacavir sulfate  Approved  PI  600  ‐  77  0.39  0.03  III 
amprenavir  Approved  PI  2800  ‐  0.04  2.43  280  II 
atazanavir sulfate  Approved  PK Boost  400  slightly soluble  1  4.54  1.6  II 
cobicistat  Approved  PI  150  ‐  0.1  5.7  6  II 
delavirdine (mesylate)  Approved  NNRTI  1200  ‐  2.94  1.02  1.63  IV 
didanosine  Approved  NRTI  400  ‐  27.3  0.04  0.06  III 
dolutegravir  Approved  INSTI  100  slightly soluble  1  1.1  0.4  III 
efavirenz  Approved  NNRTI  600  < 10‐3  0.001  4.46  2400  II 
elvitegravir  Approved  INSTI  150  <3x10‐4  0.0003  4.67  2000  II 
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Table 7 Continued. 
Drug Name 
US Regulatory 
Status*   
(as of Dec 4 2014) 
Mechanism 
of Action 
Max 
Dose† 
(mg) 
Solubility 
Definition 
(from literature) 
For Do Calculation  Dose 
Number
(Do) 
Provisional 
BCS Class Solubility 
(mg/mL)  logP 
emtricitabine  Approved  NRTI  240  ‐  112  ‐0.9  0.01  III 
etravirine  Approved  NNRTI  400  practically insoluble  0.01  5.54  160  II 
fosamprenavir calcium  Approved  PI  2800  ‐  0.31  1.98  36.13  II 
indinavir sulfate  Approved  PI  2400  very soluble  1000  2.81  0.01  I 
lamivudine  Approved  NRTI  300  ‐  70  ‐1.1  0.02  III 
maraviroc  Approved  Entry  600  highly soluble  1000  3.63  0.002  I 
nelfinavir mesylate  Approved  PI  2500  slightly soluble  1  4.72  10  II 
nevirapine  Approved  NNRTI  400  practically insoluble  0.01  2.49  160  II 
raltegravir potassium  Approved  INSTI  800  soluble  33  ‐0.39  0.097  III 
rilpivirine hydrochloride  Approved  NNRTI  25  practically insoluble  0.01  5.47  10  II 
ritonavir  Approved  PI  1200  practically insoluble  0.01  5.98  480  II 
saquinavir mesylate  Approved  PI  2000  ‐  2.22  3.8  4  II 
stavudine  Approved  NRTI  80  soluble  33  ‐0.23  0.010  III 
tenofovir disoproxil 
fumarate  Approved  NRTI  300  ‐  13.4  ‐3.7  0.09  III 
zidovudine  Approved  NRTI  600  ‐  20.1  ‐0.3  0.12  III 
* For HIV/AIDS‐related indication 
† Without consideraƟon to special populaƟons 
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Each of the 34 single-entity HIV drug products was classified as either 
high or low permeability by comparison of the in silico partition coefficient value 
to that of the reference drug metoprolol. Drugs with LogP values greater than or 
equal to 1.632 were classified as high-permeability drugs.  As shown in Figure 
20A, 53% of the drugs in single-entity HIV drug products were categorized as 
high permeability. 
Dose numbers were calculated using solubility values from the literature 
and the maximum dose strength of each oral, single-entity HIV immediate-
release drug product.  A total of 38% of the drugs were classified as high-
solubility drugs using the maximum dose strengths (Figure 20B).   
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Figure 20  Permeability and Solubility of Single-Entity HIV Drug Products 
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Provisional BCS Classification of Single-Entity Antiretroviral Drug Products 
Provisional BCS classification (Table 8) was determined using the in 
silico partition coefficients as well as the solubility data from the reference 
literature, as described in the  
Materials and Methods.  BCS Class II and Class IV were further 
subclassified as a, b, c or acid, base, neutral, respectively, according to their pKa 
values, per the subclassifications proposed by Tsume et al [90].   Only 6% of 
HIV single-entity drug products that are currently approved or in late stage 
development are BCS Class I and an additional 32% are BCS Class III drugs.  
Thus, 38% of these drug products are potentially eligible for biowaivers using 
dissolution data under the current regulatory framework.  The establishment of 
suitable in vivo predictive, in vitro dissolution methods could substantially 
expedite the development of antiretroviral drug products. 
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Table 8  Provisional BCS Classification/Subclassification of Single-Entity 
Antiretroviral Drugs 
Drug Name 
Provisional 
BCS 
Class/Subclass 
apricitabine IVc 
cabotegravir IVc 
cenicriviroc IIc 
doravirine IIc 
elvucitabine III 
festinavir IVc 
fostemsavir IVc 
naltrexone III 
tenofovir alafenamide IIc 
abacavir sulfate III 
amprenavir IIc 
atazanavir sulfate IIc 
cobicistat IIb 
darunavir IIc 
delavirdine (mesylate) IVc 
didanosine III 
dolutegravir III 
efavirenz IIc 
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Table 8 Continued. 
Drug Name 
Provisional 
BCS 
Class/Subclass 
elvitegravir IIa 
emtricitabine III 
etravirine IIc 
fosamprenavir calcium IIa 
indinavir sulfate I 
lamivudine III 
maraviroc I 
nelfinavir mesylate IIb 
nevirapine IIc 
raltegravir potassium III 
rilpivirine hydrochloride IIc 
ritonavir IIc 
tenofovir disoproxil fumarate III 
zidovudine III 
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Assessment of Fixed Dose Combinations of Antiretroviral Drug Products 
Twenty-two (22) fixed dose combinations (including single tablet 
regimens) of single-entity drug products were identified as being in late stage 
clinical development (Phase 2 or beyond) or currently marketed for an HIV 
indication.  Of these 22 drug products, 27% have yet to be fully or tentatively 
approved (Table 9). Interestingly, based solely on the current general treatment 
guidelines [37] alone, 9 of these fixed dose combinations could potentially be 
developed as single tablet regimens for ART-naïve patients:  efavirenz / 
emtricitabine / tenofovir disoproxil fumarate; lamivudine / nevirapine / stavudine; 
lamivudine / nevirapine / zidovudine; efavirenz / lamivudine / tenofovir disoproxil 
fumarate; emtricitabine / rilpivirine / tenofovir disoproxil fumarate;  
cobicistat/elvitegravir / emtricitabine / tenofovir disproxil fumarate;  abacavir 
sulfate / dolutegravir / lamivudine; cobicistat / darunavir / emtricitabine / tenofovir 
alafenamide; and cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide. 
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Table 9  US Regulatory Status of HIV Indication and Antiretroviral 
Mechanisms of Action for Fixed-Dose Combination Drug Products 
Drug Combination Mechanisms of Action US Regulatory Status 
lamivudine / raltegravir NRTI + INSTI Development 
cobicistat / elvitegravir / 
emtricitabine / tenofovir 
alafenamide 
NRTI + INSTI (+PK Boost) Development 
atazanavir sulfate / cobicistat PI (+PK Boost) Development 
emtricitabine / tenofovir 
alafenamide NRTI Development 
cobicistat / darunavir / 
emtricitabine / tenofovir 
alafenamide 
NRTI + PI (+PK Boost) Development 
cobicistat / darunavir PI (+PK Boost) Development 
lamivudine / zidovudine NRTI Approved 
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Table 9 Continued. 
Drug Combination Mechanisms of Action US Regulatory Status 
abacavir sulfate / dolutegravir 
/ lamivudine NRTI + INSTI Approved 
cobicistat / elvitegravir / 
emtricitabine / tenofovir 
disproxil fumarate 
NRTI + INSTI (+PK Boost) Approved 
lopinavir / ritonavir PI (+PK Boost) Approved 
abacavir sulfate / lamivudine / 
zidovudine NRTI Approved 
emtricitabine / tenofovir 
disoproxil fumarate NRTI Approved 
emtricitabine / rilpivirine / 
tenofovir disoproxil fumarate NRTI + NNRTI Approved 
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Table 9 Continued. 
Drug Combination Mechanisms of Action US Regulatory Status 
efavirenz / lamivudine / 
tenofovir disoproxil fumarate NRTI + NNRTI 
Tentatively 
Approved 
lamivudine / nevirapine / 
zidovudine NRTI + NNRTI 
Tentatively 
Approved 
lamivudine / nevirapine / 
stavudine NRTI + NNRTI 
Tentatively 
Approved 
lamivudine / stavudine NRTI Tentatively Approved 
efavirenz /emtricitabine / 
tenofovir disoproxil fumarate NRTI + NNRTI Approved 
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Table 9 Continued. 
Drug Combination Mechanisms of Action US Regulatory Status 
atazanavir sulfate / ritonavir PI (+PK Boost) Tentatively Approved 
darunavir / ritonavir PI (+PK Boost) Not Approveda 
lamivudine / tenofovir 
disoproxil fumarate NRTI 
Tentatively 
Approved 
abacavir sulfate / lamivudine NRTI Approved 
a Approved ex-US 
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Table 10 Provisional Data for Antiretroviral Fixed Dose Combinations 
Combination  Components 
Max 
FDC 
Dose†
(mg) 
Solubility 
Definition 
(from literature) 
For Do Calculation  Dose 
Number
(Do) 
Provisional 
BCS   
Classification 
(Constituents) 
Provisional 
BCS 
Classification 
(Combination) 
Solubility   
(mg/mL)  logP   
lamivudine / 
raltegravir 
lamivudine  300  ‐  70  ‐1.1  0.02  III 
III 
raltegravir  600  soluble  33  ‐0.39  0.07  III 
cobicistat / 
elvitegravir / 
emtricitabine / 
tenofovir alafenamide 
cobicistat  150  ‐  0.1  5.7  6  II 
Mixed 
(II, III) 
elvitegravir  150  <3x10‐4  0.0003  4.67  2000  II 
emtricitabine  200  ‐  112  ‐0.9  0.01  III 
tenofovir alafenamide  10  ‐  0.00003  1.88  1285.46  II 
atazanavir sulfate / 
cobicistat 
atazanavir sulfate  300  slightly soluble  1  4.54  1.2  II  II 
cobicistat  150  ‐  0.1  5.7  6  II 
emtricitabine / 
tenofovir alafenamide 
emtricitabine    200  ‐  112  ‐0.9  0.01  III  Mixed 
(II, III) tenofovir alafenamide  25  ‐  0.00003  1.88  3213.66  II 
cobicistat / darunavir 
/ emtricitabine / 
tenofovir alafenamide 
cobicistat    150  ‐  0.1  5.7  6  II 
Mixed 
(II, III) 
darunavir  800  ‐  0.15  2.82  21.33  II 
emtricitabine  200  ‐  112  ‐0.9  0.01  III 
tenofovir alafenamide  10  ‐  0.00003  1.88  1285.46  II 
cobicistat / darunavir  cobicistat  150  ‐  0.1  5.7  6  II  II 
darunavir  800  ‐  0.15  2.82  21.33  II 
darunavir / ritonavir 
darunavir  400  ‐  0.15  2.82  10.67  II 
II 
ritonavir  50 
practically 
insoluble  0.01  5.98  20  II 
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Table 10 Continued. 
Combination  Components 
Max 
FDC 
Dose†
(mg) 
Solubility 
Definition 
(from literature) 
For Do Calculation  Dose 
Number
(Do) 
Provisional 
BCS   
Classification 
(Constituents) 
Provisional 
BCS 
Classification 
(Combination) 
Solubility   
(mg/mL)  logP   
efavirenz / lamivudine 
/ tenofovir disoproxil 
fumarate 
efavirenz  600  < 10‐3  0.001  4.46  2400  II 
Mixed 
(II, III) lamivudine  300  ‐  70  ‐1.1  0.02  III tenofovir disoproxil 
fumarate  300  ‐  13.4  ‐3.7  0.09  III 
lamivudine / 
nevirapine / 
zidovudine 
lamivudine  150  ‐  70  ‐1.1  0.01  III 
Mixed 
(II, III) nevirapine  200 
practically 
insoluble  0.01  2.49  80  II 
zidovudine  300  ‐  20.1  ‐0.3  0.06  III 
lamivudine / 
nevirapine / 
stavudine 
lamivudine  150  ‐  70  ‐1.1  0.01  III 
Mixed 
(II, III) nevirapine  200 
practically 
insoluble  0.01  2.49  80  II 
stavudine  30  soluble  33  ‐0.23  0.004  III 
lamivudine / 
stavudine 
lamivudine  150  ‐  70  ‐1.1  0.01  III  III 
stavudine  30  soluble  33  ‐0.23  0.004  III 
lamivudine / 
tenofovir disoproxil 
fumarate 
lamivudine  300  ‐  70  ‐1.1  0.02  III 
III tenofovir disoproxil 
fumarate  300  ‐  13.4  ‐3.7  0.09  III 
atazanavir sulfate / 
ritonavir 
atazanavir sulfate  300  slightly soluble  1  4.54  1.2  II 
II 
ritonavir  100 
practically 
insoluble  0.01  5.98  40  II 
lamivudine / 
zidovudine 
lamivudine  300  ‐  70  ‐1.1  0.02  III 
III 
zidovudine  600  ‐  20.1  ‐0.3  0.12  III 
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Table 10 Continued. 
Combination  Components 
Max 
FDC 
Dose†
(mg) 
Solubility 
Definition 
(from literature) 
For Do Calculation  Dose 
Number
(Do) 
Provisional 
BCS   
Classification 
(Constituents) 
Provisional 
BCS 
Classification 
(Combination) 
Solubility   
(mg/mL)  logP   
abacavir sulfate / 
dolutegravir / 
lamivudine 
abacavir sulfate  600  ‐  77  0.39  0.03  III 
III dolutegravir  100  slightly soluble  1  1.1  0.40  III 
lamivudine  300  ‐  70  ‐1.1  0.02  III 
cobicistat / 
elvitegravir / 
emtricitabine / 
tenofovir disproxil 
fumarate 
cobicistat  150  ‐  0.1  5.7  6  II 
Mixed(II, III) elvitegravir 
150  <3x10‐4  0.0003  4.67  2000  II 
emtricitabine  200  ‐  112  ‐0.9  0.01  III 
tenofovir disoproxil 
fumarate  300  ‐  13.4  ‐3.7  0.09  III 
lopinavir / ritonavir  lopinavir   
800  practically insoluble  0.01  4.69  320  II 
II 
ritonavir  200 
practically 
insoluble  0.01  5.98  80  II 
abacavir sulfate / 
lamivudine / 
zidovudine 
abacavir sulfate  600  ‐  77.0  0.39  0.03  III 
III lamivudine    300  ‐  70  ‐1.1  0.02  III 
zidovudine  600  ‐  20.1  ‐0.3  0.12  III 
emtricitabine / 
tenofovir disoproxil 
fumarate 
emtricitabine  200  ‐  112  ‐0.9  0.01  III 
III tenofovir disoproxil 
fumarate  300  ‐  13.4  ‐3.7  0.09  III 
emtricitabine / 
rilpivirine / tenofovir 
disoproxil fumarate 
emtricitabine  200  ‐  112  ‐0.9  0.01  III 
Mixed 
(II, III) rilpivirine  25 
practically 
insoluble  0.01  5.47  10  II 
tenofovir disoproxil 
fumarate  300  ‐  13.4  ‐3.7  0.09  III 
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Table 10 Continued. 
Combination  Components 
Max 
FDC 
Dose†
(mg) 
Solubility 
Definition 
(from literature) 
For Do Calculation  Dose 
Number
(Do) 
Provisional 
BCS   
Classification 
(Constituents) 
Provisional 
BCS 
Classification 
(Combination) 
Solubility   
(mg/mL)  logP   
efavirenz 
/emtricitabine / 
tenofovir disoproxil 
fumarate 
efavirenz  600  < 10‐3  0.001  4.46  2400  II 
Mixed 
(II, III) emtricitabine  200  ‐  112  ‐0.9  0.01  III tenofovir disoproxil 
fumarate  300  ‐  13.4  ‐3.7  0.09  III 
abacavir sulfate / 
lamivudine 
abacavir sulfate  600  ‐  77  0.39  0.03  III 
III 
  lamivudine  300  ‐  70  ‐1.1  0.02  III 
* For HIV/AIDS‐related indication 
† Without consideraƟon to special 
populations               
^ Approved ex‐US 
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Provisional BCS Classification of Fixed Dose Combinations of Antiretroviral 
Drug Products 
Provisional BCS classification of each of the 22 fixed dose combinations 
was determined by the provisional classification of each of the constituent single-
entity drugs within the combination (Figure 21).  In contrast to the provisionally 
classified single-entity HIV drugs, none of the fixed dose antiretroviral 
combinations were BCS Class I.  This means that none of these combination 
drug products would have been eligible for biowaivers in the United States prior 
to the implementation of FDA’s 2015 draft guidance.  However, 36% of the 
drugs were BCS Class III and now potentially eligible for biowaivers of in vivo 
bioequivalence studies from the EMA as well as the FDA.   These results also 
point to the substantial improvement that in vivo predictive, in vitro dissolution 
methods could potentially offer with regard to reducing the clinical requirements, 
often associated with longer development timelines and higher costs [84], for 
fixed dose antiretroviral drug combinations of established single-entity drug 
products. 
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Figure 21  Provisional BCS Classification of Antiretroviral Fixed Dose 
Combinations 
 
Provisional BCS classifications of fixed dose combinations wer determined 
according to the provisional BCS classifications of the constituent drugs.  
If all drugs in the combination were of the same BCS class, then the fixed 
dose combination was assigned the same provisional BCS classification.  
If the drugs in combination were of different BCS classes, the fixed dose 
combination was assigned a provisional “mixed class” that represented 
the BCS classification of all of the constituent drugs.   
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Discussion 
In this work, we assessed the biopharmaceutical properties of established 
and investigational antiretroviral drug products for the treatment of HIV infection.  
Our research identified 34 single-entity drug products and 22 fixed-dose, co-
formulated, combination drug products with HIV indications in late stage clinical 
development (Phase 2 or beyond) or post-marketing phase.  Among the 
products assessed, no major difference was seen in the proportion of products 
already approved as single-entity or fixed dose combinations – 26% of single 
drug products and 27% of co-formulated combination drug products have yet to 
be registered or tentatively approved.  These data suggest that, although there 
is increasing awareness regarding the potential advantages of fixed dose 
combination antiretroviral regiments, to-date there is still a comparable level of 
interest in developing new products with a single active ingredient for the 
treatment of HIV infection.  However, in light of the HHS treatment guidelines 
and the expansion of regulatory waivers for in vivo bioequivalence data to fixed 
dose combinations comprised of BCS Class I and/or Class III drugs, there is 
opportunity for the development of new fixed dose combination antiretroviral 
regimens based on existing data from standalone, single-entity products.  
For fixed dose combinations based on products with a single antiretroviral 
API, which have an established safety and efficacy profile for co-administration 
with other drug products for the treatment of HIV infection, expanding the range 
of BCS-based biowaiver criteria has the potential to significantly lessen the 
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amount of in vivo data needed to support literature-based marketing applications, 
such as those permitted in the U.S. under Section 505(b)(2) of the Federal Food, 
Drug and Cosmetic Act.  In fact, 21% of the fixed dose combinations assessed 
herein were approved/tentatively approved in the United States as a 505(b)(2) 
application. This potential regulatory pathway has greater potential for challenges 
due to patent protection, but even in cases where the existence of patents and/or 
market exclusivity in the United States would preclude approval and market 
accessibility, new antiretroviral fixed dose combination products can still 
potentially be developed for ex-US distribution under the FDA’s President’s 
Emergency Plan for AIDS Relief (PEPFAR) initiative, which was established in 
2004 to ensure that antiretroviral drugs distributed under the Presidents' Plan 
would be safe, effective, and manufactured to quality standards [91].  Similarly, 
recognizing that patent laws, which vary globally, could undermine the goal of 
improving access to priority medicines, the WHO Prequalification Programme 
does not operate with respect to product patents [92]. Of note, one-third of the 
fixed dose combinations included in this provisional evaluation have been 
tentatively approved in the U.S. under PEPFAR and 36% of the combinations are 
included on the WHO’s 12th Invitation to Submit an Expression of Interest (EOI) 
for product prequalification.  Thus, our provisional assessment can be utilized to 
build a case for how global accessibility to priority co-formulated antiretroviral 
drug products may be improved through the development of scientific 
justifications for in vitro methodology, in lieu of additional in vivo data, to 
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demonstrate bioequivalence between co-administered single-entity drug products 
and co-formulations in the same dosage form.   
As exemplified by the extension of the biowaiver eligibility to BCS Class 
III drugs, regulatory science continues to evolve. It is generally well-recognized 
that regulators appear to be moving toward harmonization in their interpretations 
and willingness to consider alternative approaches with scientific merit.  And 
even though the WHO currently specifies abacavir, emtricitabine, lamivudine, 
stavudine, zidovudine, and combinations thereof as the only antiretroviral 
medicines eligible for biowaivers under the Prequalification Programme, the 
WHO also broadly invites manufacturers to explore opportunities to demonstrate 
eligibility for biowaivers by providing evidence to classify the API(s) as either 
BCS Class I or Class III [85].  Our provisional assessment revealed that 36% of 
the co-formulated drug combinations (none of which were comprised of Class I 
drugs) were potentially eligible for BCS-based biowaivers, which emphasizes the 
fact that there is still significant opportunity with regard to the pharmaceutical and 
regulatory science surrounding fixed dose combinations.  Additional scientifically 
sound approaches for demonstrating bioequivalence can help influence the 
direction in which the field progresses.  Although regulatory authorities have yet 
to propagate guidelines to confirm the acceptability of alternate in vitro data in 
place of in vivo bioequivalence studies for BCS Class II and Class IV drugs, the 
scientific community has been making progress in establishing in vivo predictive 
and physiologically relevant dissolution methodologies [93].  If scientifically valid 
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in vitro approaches are developed to justify waivers for in vivo bioequivalence 
studies in support of combinations of drugs from BCS Class II and/or IV, for 
example, there is tremendous opportunity for simplifying the regulatory pathway 
and laying the ground work for advancing global access to more antiretroviral 
fixed-dose combination drug products.    
Regardless of the drugs’ BCS classifications, a well-designed oral fixed-
dose combination drug product comprised of individual drugs that exhibit linear 
and non-interacting ADME should, in theory, demonstrate the same in vivo 
dissolution and absorption profiles as the constituent, single-entity drug products 
co-administered in the same dosage forms if there are no interfering excipients in 
the fixed dose formulation.  This type of in vitro comparison should especially be 
more feasible for antiretroviral products where the in vivo behavior of various 
combinations is commonly established via clinical studies provided in marketing 
applications to support co-administration with other antiretroviral products in the 
indication and/or dosing recommendations. Therefore, appropriately-designed in 
vitro dissolution methodology comparing each API should be sufficient to 
demonstrate bioequivalence between co-formulated oral drug combinations and 
the corresponding co-administered single-entity products in the same dosage 
forms.   
As our study revealed that the majority (41%) of the antiretroviral fixed 
dose drug co-formulations are mixtures of drugs of different BCS classes, 
combinations/hybrids of physiologically-relevant dissolution approaches 
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measuring each API according to the dissolution method recommended for the 
single-entity drug represent one scientifically valid alternative to in vivo 
bioequivalence for fixed dose combinations.  Utilizing the starting 
recommendations for in vivo predictive dissolution apparatus and media 
proposed according to BCS subclassification by Tsume et al [90], for example, 
some initial dissolution parameters can be recommended as a starting place for 
assessing the bioavailability of fixed dose combinations with mixed BCS 
classification (i.e., drugs from more than one BCS Class in the combination) 
relative to reference single-entity products administered together(Table 11).  
Depending on the combination, multiple tests could be utilized or even combined 
so that each API is assessed according to the dissolution method recommended 
for the single-entity drug product. 
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Table 11  Starting Recommendations for Design of in vivo Predictive in vitro Dissolution Methodology for 
Fixed Dose Combinations Comprised of APIs with Different BCS Classifications 
 
Mixed BCS 
Classifications / 
SubClassifications 
# of 
Tests 
Gastric 
Medium 
Consider 
Gastric 
Compartment
Intestinal Luminal Medium 
Consider 
Absorption 
Compartment
I and IIa, IVa, IIb, 
and/or IVb 
Test 1: 250 ml PGBa No 900 ml PIBb No 
Test 2: 250 ml PGB Yes 100 ml PIB Yes 
I and IIc and/or IVc 
Test 1: 250 ml PGB No 900 ml PIB No 
Test 2: 250 ml PGB Yes 100 ml PIB + bile acids/lipid Yes 
I and III 
Test 1: 250 ml PGB No 900 ml PIB No 
Test 2: 250 ml PGB No 100ml PIB No 
IIa, IIb, IVa and/or IVb Test 1: 250 ml PGB Yes 100 ml PIB Yes 
IIa, IIb, IVa, and/or IVb 
and III 
Test 1: 250 ml PGB Yes 100 ml PIB Yes 
Test 2: 250 ml PGB No 100ml PIB No 
a Physiological gastric buffer 
b Physiological intestinal buffer 
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Table 11 Continued. 
Mixed BCS 
Classifications / 
SubClassifications 
# of 
Tests 
Gastric 
Medium 
Consider 
Gastric 
Compartment
Intestinal Luminal Medium 
Consider 
Absorption 
Compartment
IIc and IVc Test 1: 250 ml PGB Yes 100 ml PIB + bile acids/lipid Yes 
IIa, IIb, IVa and/or IVb 
and IIc and/or IVc 
Test 1: 250 ml PGB Yes 100 ml PIB Yes 
Test 2: 250 ml PGB Yes 100 ml PIB + bile acids/lipid Yes 
IIc and/or IVc and III 
Test 1: 250 ml PGB Yes 100 ml PIB + bile acids/lipid Yes 
Test 2: 250 ml PGB No 100ml PIB No 
I and IIa, IIb, IVa, 
and/or IVb and IIc 
and/or IVc 
Test 1: 250 ml PGB No 900 ml PIB No 
Test 2: 250 ml PGB Yes 100 ml PIB Yes 
Test 3: 250 ml PGB Yes 100 ml PIB + bile acids/lipid Yes 
I and IIa, IIb, IVa, 
and/or IVb and III 
Test 1: 250 ml PGB No 900 ml PIB No 
Test 2: 250 ml PGB Yes 100 ml PIB Yes 
Test 3: 250 ml PGB No 100ml PIB No 
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Table 11 Continued. 
 
Mixed BCS 
Classifications / 
SubClassifications 
# of 
Tests 
Gastric 
Medium 
Consider 
Gastric 
Compartment
Intestinal Luminal Medium 
Consider 
Absorption 
Compartment
I and IIc and/or IVc 
and III 
Test 1: 250 ml PGB No 900 ml PIB No 
Test 2: 250 ml PGB Yes 100 ml PIB + bile acids/lipid Yes 
Test 3: 250 ml PGB No 100ml PIB No 
I and IIa, IIb, IVa, 
and/or IVb and IIc 
and/or IVc and III 
Test 1: 250 ml PGB No 900 ml PIB No 
Test 2: 250 ml PGB Yes 100 ml PIB Yes 
Test 3: 250 ml PGB Yes 100 ml PIB + bile acids/lipid Yes 
Test 4: 250 ml PGB No 100ml PIB No 
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As a therapeutic area with an established clinical rationale [37] [82] and 
history of regulatory approvals for co-administered drug products, [79] we are 
promoting the utility of alternative approaches to justify biowaivers for fixed dose 
combinations of antiretrovirals – especially in cases where existing data from 
standalone, single-entity products can be leveraged to justify that in vitro 
bioavailability correlates with in vivo bioequivalence.  Although antiretroviral 
drug products were assessed in this work, these findings and recommendations 
are relevant to the development of fixed-dose combination drug products in 
general.  If scientifically-justified, in vivo predictive dissolution methodology can 
be developed, there is great potential to broadly simplify and accelerate the 
development of both generic formulations and new fixed dose drug combinations 
of established drugs.  The availability of these additional drug products, 
developed with scientifically valid in vitro data to confirm the validity of 
extrapolating existing in vivo data to these new formulations, should help improve 
global access to priority medicines in order to address unmet medical needs.  
Conclusion 
This work presents a provisional assessment of the biopharmaceutical 
characteristics of drug products in the late stages of clinical development and/or 
in the post-market phase for antiretroviral indications in order to emphasize how 
in vitro dissolution strategies can be scientifically valid approaches for 
demonstrating bioequivalence between co-formulated drug products and the 
reference, single-entity products administered in combination.  Baseline 
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recommendations have been presented herein as a starting place for developing 
in vivo predictive and scientifically valid in vitro dissolution methodology to 
assess fixed dose combinations of various BCS classes.  Thus, by promoting 
the utility of theoretically viable scientific rationale to support simpler and 
abbreviated development pathways, we are highlighting potential opportunities to 
increase the availability of co-formulated antiretroviral drug products and 
describing mechanisms by which drug manufacturers and regulators can 
implement science-based approaches to address unmet medical needs and 
effectively treat some of the world’s deadliest diseases – especially in developing 
countries. 
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CHAPTER 6 
 
FINAL CONCLUSIONS 
Conclusions – Part I 
The first part of this body of work demonstrates the importance of 
molecular mechanisms mediated by HIV-1 envelope expression, which 
substantially impact the apparently low infectivity of HIV-1.   
The initial studies to assess how defective virions might be contributing to 
the overall observed low infectivity of HIV-1 and demonstrated that the 
production of defective virions is not solely attributable to mutations introduced in 
the reverse transcription step of virus replication.  Instead, the data clearly 
demonstrated that unfavorable envelope glycoprotein stoichiometry can result in 
“defective” HIV-1.  The findings are consistent with prior reports of the role of 
biophysical instability and of envelope glycoprotein stoichiometry in HIV-1 
infectivity decay, but demonstrate that, overall, the low infectivity of HIV-1 
primarily results from other mechanism(s).
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Subsequent studies help clarify these mechanisms.  First by 
demonstrating that, although commonly interpreted as independent events, HIV-
1 interactions with a target cell are in fact, influenced to some extent by the 
presence of other virus particles.  Additional results not only show that the 
extent of non-specific interactions between HIV-1 and target cells increases in 
accordance with the multiplicity of virus particles, but that these non-specific 
interactions impair infection efficiency and promote the degradation of virus 
particles that have been endocytosed through envelope-independent 
mechanisms.  
Hence, this work achieves its primary objective to investigate the 
molecular mechanisms that form the basis of HIV-1 infectivity and has proven the 
initial hypothesis that HIV-1 infectivity is limited by the ability to efficiently engage 
target cell because of the low density of envelope spike glycoproteins on virus 
particles.  The evidence presented herein offers explanation of molecular 
mechanisms that underlie HIV-1 infectivity.  As these results offers unique 
perspective for understanding HIV-1 infection efficiency and highlight 
considerations of clinical import, they lay the foundation for better strategies for 
treating HIV-1 infection.   
Going forward, the results of these studies may influence the design of 
HIV-1 entry inhibitors and/or vaccines.  In addition, in order to further 
understanding of the virus lifecycle and potentially discover new therapeutic 
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targets, future studies should explore the role of the endocytic pathways (as 
highlighted in this work and previous reports) in HIV-1 pathogenesis. 
Conclusions – Part II 
The second part of this body of work demonstrates the utility of in vivo 
predictive and scientifically valid in vitro dissolution methodology to assess fixed 
dose combinations of various BCS classes in order to support simpler and 
abbreviated development pathways for co-formulated, fixed-dose combination 
drug products.   
To motivate regulatory and scientific advancement with regard to 
requirements for bioequivalence, the work provided herein provisionally classifies 
and presents an assessment of the biopharmaceutical properties of 34 single-
entity and 22 fixed-dose, co-formulated, combination oral drug products in late 
stage clinical development (Phase 2 or beyond) or post-marketing phase for HIV 
indications.  To be effective in treating this deadly disease, HIV antiretroviral 
therapy combines the effect of multiple mechanisms of antiviral activity through 
co-administration of single-entity drug products or, when available, simpler 
administration of fixed-dose co-formulations.  Consistent with treatment 
guidelines, which generally recommend nucleoside reverse transcriptase 
inhibitors as the backbone to an effective antiretroviral regimen in treatment-
naïve patients, NRTIs represented the most common class among the single-
entity drug products assessed, as the antiretroviral activity of 11 out of the 34 (i.e., 
32%) can be attributed to this mechanism of action.  Based solely on the current 
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general treatment guidelines [37] alone, 9 of these fixed dose combinations could 
potentially be developed as single tablet regimens for ART-naïve patients.  As 
there is a significant global, unmet medical need for access to antiretroviral 
therapy, efforts to enable simplified and/or abridged development pathways may 
substantially improve the availability of these essential medicines.     
Current regulatory guidelines permit waivers of in vivo bioequivalence 
studies for immediate-release orally administered products comprised of drug 
substances that are highly soluble, according to the BCS Classification System.  
Our provisional assessment revealed that 38% of the single-entity drug products 
and 36% of the co-formulated drug combinations are comprised of high solubility 
compounds and are, therefore, potentially eligible for BCS-based biowaivers 
under the existing regulatory framework.  In theory, however, in vitro data could 
be used to justify biowaivers, regardless of BCS classification.  Such a 
theoretical opportunity is especially relevant to the development  of fixed-dose 
combinations of single-entity products that have an established safety and 
efficacy profile for co-administration, which is the case for many antiretroviral 
drug products, because the otherwise required in vivo studies analyzing each 
active moiety are inherently more complex, time consuming, and expensive.   
Thus, this provisional assessment highlights opportunities to utilize 
scientifically-valid in vitro dissolution strategies to demonstrate bioequivalence 
between co-formulated drug products and the reference, single-entity products 
administered in combination. Going forward, as dissolution methodologies with in 
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vivo relevancy are developed, this work lays the foundation for in vitro 
assessments of bioequivalence to broadly replace the complex in vivo studies 
currently required for drug combinations; and, as a result, can lead to increased 
availability of more effective combination drug products, especially in developing 
countries where such products can help address health care disparities and 
significant unmet medical need.  
Overall Conclusions and Significance 
Overall, in order to contribute to the advancement of antiretroviral therapy, 
this dissertation presents research pertaining to both early- and late-stage 
antiviral product development by: (1) emphasizing opportunities for molecular 
targeting to impede HIV infection and (2) providing a biopharmaceutical rationale 
to accelerate the development of co-formulated antiretroviral drug products.   
The following research objectives were accomplished, as elaborated in 
this dissertation: 
• Production, characterization, and optimization of the infectivity of 
single-cycle HIV-1, 
• Quantitation of the efficiency of HIV-1 infection, 
• Investigation of envelope-dependent mechanism(s) influencing 
HIV-1 binding/infection, 
• Provisional biopharmaceutical subclassification of single-entity and 
fixed dose antiretroviral combination drug products, and  
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• Quantitative impact assessment to support scientific rationale for 
abbreviated bioequivalence and dissolution testing 
recommendations for single-entity and fixed-dose antiretroviral 
combination drug products. 
 The results from both aspects of this research provide a current and 
forward-looking view of antiretroviral therapy that will aid the development of 
therapeutic approaches to combat one of the world’s most serious viral infections.
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